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Development of protective immunity against many pathogens requires fine 
orchestration of both humoral- as well as cell mediated-immunity. While, circulating 
antibodies play crucial role in the elimination of extracellular infections, majority of 
intracellular infections {e.g. malaria, leishmaniasis, candidiasis etc.) require generation of 
CDS* cytotoxic T-cells (CTL) in conjunction to strong CD4* T-helper cells (Th) because 
such pathogens adapt intracellular parasitism as a strategy to avoid recognition by 
antibodies. Besides, some pathogens {e.g. Plasmodium sp. Chlamydia sp, HIV) introduce 
substantial antigenic variations, which further complicate the process of vaccine 
designing. Ironically, a typical protocol followed in immunization with soluble antigens 
leads to the induction of humoral immune response mainly. In contrast activation of the 
cell-mediated immune response, upon administration of soluble antigens has remained an 
uphill task. This requires strategies to expose antigens to the proteasome machinery, a 
multifunctional protease complex in the cytosol of the APCs, as degradation of protein 
antigens by the cytosolic proteolytic system forms the cardinal step involved in the 
induction of cytotoxic T lymphocytes (CTLs). Therefore to generate a CDS* T-
lymphocyte response, this is a prerequisite to delivery antigens into the cytosol of the 
APCs, which is further followed by its processing and presentation along with class 1 
major histocompatibility complex (MHC 1) molecules. The present study has been 
planned to fulfill the requirement of eliciting desired immune responses against various 
intracellular infections and has been presented in two parts. 
In the first part of the study, we describe a novel method of liposome-based 
vehicle to deliver macromolecules into the cytosol of the target cells. To develop safe and 
effective methods for antigen delivery, we exploited the fusogenic potential of the lipids 
derived from a lower organism, i.e. Escherichia coli (K-12). These lipids were shown to 
induce strong membrane-membrane fusion as evident from resonance energy transfer as 
well as content mixing assays. The degree of fusion with model membrane systems using 
E. coli lipid liposomes (escheriosomes) varied from 40-60%, in contrast to 1-8% 
observed with EPC/chol (egg derived phosphatidylcholine/cholesterol) lipid vesicles, 
depending upon the assay system used. The fusion of escheriosomes with macrophages 
(J774 A.l) was assessed by observing transfer of fluorescent membrane marker (NBD-PE) 
10 J774 A.l cells. Transfer of the membrane fluorescent marker (NBD-PE) by 
escheriosomes to the membranes of J774 A.l cells suggested that these vesicles interact 
by membrane-membrane fusion mode. This was further demonstrated by observed 
inhibition of cellular protein synthesis among J774 A.l cells using escheriosome 
encapsulated 'ricin A'. Thus, it may be concluded that the escheriosomes can 
spontaneously fuse with the membrane of macrophages to deliver a significant portion of 
their contents into the cytoplasmic compartment of the cells. 
In the second part, we evaluated the escheriosomes as an antigen delivery system 
in the immunization studies against blood stage infection of lethal Plasmodium yoelii 
(MDR) in BALB/c mice. Today, malaria is considered one of the most devastating and 
deadly disease that claim about 1.4 to 2.7 million deaths annually. Furthermore, the 
recent development of resistance of Plasmodium sp. to the chemotherapeutic agents and 
of its vector to DDT, alann us to opt for alternative weapons for its control. This has led 
to choose prophylactic measures as complementary tools for controlling this dreadful 
disease, which in turn requires understanding of the basic immunological complexities 
involved in the resolution of the disease. However, in spite of the numerous efforts made 
for developing malaria vaccine, no effective malaria vaccine is available today. 
It has been shown that elimination of liver stage Plasmodium infection require 
involvement of CDS' CTL response, while immunity against blood stages of malaria is 
dependent on IFN-y secreting CD4"^  Th-cells and IgG2a isotype of antibodies. In the 
study, soluble blood stage antigens off*, yoelii (sAg) were encapsulated in escheriosomes 
or EPC/chol liposomes and BALB/c mice were immunized at various days for 
performing protection as well as immunological studies. Other experimental groups 
received sAg with incomplete Freund's adjuvant (IFA), while control groups were 
injected with empty escheriosomes (sham) or PBS only. Results from the study revealed 
that immunization with escheriosome entrapped sAg induced strong protective immune 
responses that successfiilly suppressed drug resistant P. yoelii infection, whereas other 
formulations of sAg such as EPC/chol liposome entrapped sAg, or sAg with incomplete 
Freund's adjuvant (IFA) failed to impart significant levels of protection. Among all the 
sAg formulations used in the study, escheriosome based vaccine elicited strongest 
humoral as well as cell mediated immune responses in immunized BALB/c mice. 
The escheriosome-sAg mediated protection was found to be associated with 
enhanced antigen specific CD4"^  and CDS* T cell populations. Furthermore, activation of 
Th-cells requires not only TCR occupancy by presented MHC-antigen complex, but also 
a set of other costimulatory signals provided by APCs. In this concern, costimulatory 
molecules (CD80 and CD86) provide maturation signals to T-lymphocytes, leading to 
their proliferation, cytokine production, and development of effector ftmctions. Higher 
expression of CD80 and CD86 on the macrophages incubated with escheriosome-sAg 
again supports the data representing the expansion of Th cells. Analysis of cytokine 
profiles in immunized animals revealed that the escheriosome mediated delivery of sAg 
was associated with the induction of a mixed Thl/Th2 (IFN-y and IL-4) cytokine 
response. Moreover, vaccination with escheriosome entrapped sAg elicited high IgGl 
and IgG2a isotype responses that played important role in imparting protection against 
blood stage infection of Plasmodium yoelii (MDR) in BALB/c mice. The antibody 
titration by indirect immunofluorescence (IIF) also revealed the presence of high titer 
parasite-specific antibodies in the sera of mice that were immunized with escheriosome 
encapsulated sAg. These high titer antibodies recognized a heterogeneous set of antigens 
on P. yoelii antigens blotted on to nitrocellulose membranes. 
The data of the present study seems to open new vistas for the use of 
escheriosome based vaccines not only against malaria but against various other 
intracellular pathogens as well. 
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In order to develop effective vaccines against pathogens causing persistent or 
chronic infections, it is a mandatory prerequisite to have better insight about immuno 
protective mechanisms that are operative in the host to prevent or control an infection. At 
first glance, development of vaccines seems to be easy and straight forward that involves 
identification of immunogenic antigens of the pathogens and finally to develop suitable 
means for immunization. However, this could be true for agents that are either 
extracellular or antigenically stable (e.g. some extracellular bacteria and poliovirus). In 
contrast, number of factors has to be considered before developing vaccines against 
pathogens that are subjected to substantial antigenic variations (e.g. Plasmodium, 
Chlamydia sp. and HIV). To a significant extent, such a need coincides with a much 
increased understanding of the properties and fianctional components of the mammalian 
immune systems. 
The two systems contributing to the mammalian immunity include the innate 
(nonspecific, nonadaptive) and the acquired (specific, adaptive) systems. The adaptive 
immune system, which developed later during evolution than the innate, differs from the 
latter in two critical properties viz. high specificity and memory, both of which are the 
exclusive hallmarks of B- and T-cells. While, B-cells are responsible for humoral 
immunity, T-cells generate cell mediated immunity against pathogens. Apart fi:om B- and 
T-cells, adaptive immune system consists of a series of specialized cells, such as 
macrophages, neutrophils, natural killer (NK) cells, dendritic cells (DCs), and different 
products, such as the cytokines; a-, P- and y-interferons (IFNs); chemokines; and larger 
proteins such as the C-reactive proteins and those of the complement cascade (Medzhitov 
and Janeway, 2000). Because of these cardinal features, the practice of vaccination 
depends utterly on the properties of the adaptive system. 
1. Role of different immune responses against infections 
Infections caused by various pathogens may be categorized on the basis of their 
extracellular or intracellular existence inside the host. In extracellular infections, 
pathogen specific antibodies can prevent as well as eliminate all the pathogens 
successfully. Moreover, cytokines secreted by CD4^ Thl cells help to activate phagocytic 
cells {e.g. macrophages) and thereby facilitate the uptake and destruction of the agent, 
either as such or complexed with antibodies (by Fc receptor mediated endocytosis or 
complement activation). Theoretically, CTLs are not expected to have a role in such 
situations. However, against intracellular infections, various unmune responses may play 
different roles in the elimination of the pathogen: 
1.1. Role of antibodies in intracellular infections 
Antibodies function as the effector molecules of the humoral response. It 
recognizes soluble or particulate antigen for its neutralization and elimination from the 
systemic circulation. Usually in extracellular infections, neutralization of the infectivity 
of the challenge agent is a critical role for specific antibodies. However, in some cases, if 
infectious agent escapes neutralization and replicates inside the host cells, antibodies are 
reported to neutralize their progeny (e.g. prevent or limit viremia) and ulthnately may 
destroy infected cells either by Antibody Dependent Cellular Cytotoxicity (ADCC) or by 
complement mediated lysis (Plotkin, 2001). Besides their role against extracellular 
infections, antibodies have also shown their efficacy against intracellular infections in 
experimental model systems, e.g. certain MAbs to the fiision protein of respiratory 
syncytial virus (RSV) were found to clear the infection in mice (Taylor, 1994). These 
antibodies may have been endocytosed into an infected cell and thus prevented viral 
replication (Chanock et al, 1993). In another example, MAbs or hyperimmune serum 
specific for Sindbis virus were able to clear the virus from infected neurons in SCID mice 
(Griffin et ah, 1992). Moreover, SCID mice infected with a low dose of egg grown 
influenza virus that caused delayed death were protected from death if transfused with 
specific antibodies (Scherle et al, 1992). Although these examples are of considerable 
interest in demonstrating a potential use for high titer antibodies, they are atypical; 
however, there are many examples of intracellular infections persisting in the presence of 
high titers of specific antibodies. 
1.2. Role of T-cell responses in intracellular infections 
T lymphocytes generated in response to a given antigen are responsible for cell-
mediated immunity. Both activated CD4^ T-helper and CD8^ T-cytotoxic lymphocytes 
serve as effector cells. The role of CD4^ T-cell responses in viral infection is difficult to 
find as this type of infection specifically requires CD8"^  CTLs (cytotoxic T lymphocytes) 
for clearance of the infection (Ada and McElrath, 1996). However, in the zosteriform 
spread model of a herpes virus type-2 infection, CD4^ Thl cells were found to protect the 
mice against cutaneous infection (Simmons and Nash, 1984). hi the same disease model, 
even CTLs mediate protection when the infection spreads to the nervous system 
(Simmons and Tscharke, 1992). Although, role of CD4^ T-cells in facilitating CDS"^  CTL 
response generation has been demonstrated experimentally, in contrast several reports are 
available that rule out such contributions of CD4"^  T-cells. For example, in CD4^ T-cells 
knockout (KO) mice, quite strong CTL responses were generated against some viral 
infections (Cardin et al., 1996). 
Surprisingly, in bacterial as well as protozoan infections, the role of a particular 
T-cell lineage (CD4"^  T-helper or CD8^ T-cytotoxic) appears to be less clear cut. For 
example in murine lysteriosis, CTLs specific for a single nonamer peptide determinant of 
the bacterial protein listeriolysin, were protective in vivo (Harty and Bevan, 1992). 
Furthermore, it has also been shown that the specific CD 8"^  T-cells, but not CD4"^  T-cells, 
lyse Listeria monocytogenes infected hepatocytes in a class I MHC restricted manner 
(Jiang et al., 1997). hi contrast in another disease model of bacterium (BCG), depletion 
of CD4^ T-cells using specific antiserum resulted in a large increase in the number of 
bacteria whereas depletion of CD8"^  T-cells apparently had little effect on the course of 
BCG infection (Pedrazzini et al., 1987). The situation became more confusing when 
another experiment using cell transfer pointed out the importance of CD4"^  T-cells in 
controlling murine Mycobacterium tuberculosis infection, where simultaneously a role 
for CD8"^  T-cells was also claimed (Leveton et ah, 1989). However, later work with P2-
microglobulin (Pain) KO (Knock-Out) mice (which can not make functional CDS T-cells) 
revealed the prime importance of CDS"^  CTLs in controlling a virulent M. tuberculosis 
infection and on the other hand, also confirmed that CTLs play no role in controlling a 
BCG infection (Flynn et al, 1993). 
Furthermore, the effect of genetic disruption in mice on the progression of 
protozoan infections has provided mixed results and except few examples no clear 
difference can be made where a definite role of either CD4'^  T-helper or CD8"^  CTL can 
be stated. Using Pam KO mice, for example no difference was found in the time course of 
infection with Plasmodium or Leishmania, whereas the infection with Trypanosoma cruzi 
was exacerbated (Amoldi and Kaufmann, 1994). 
2. Requirements for successful vaccination 
The requirement of eliciting a protective immune response against variety of 
pathogens may vary greatly as various pathogens require involvement of specific 
components of immune system for their clearance e.g. as discussed earlier, extracellular 
infections may simply be eliminated by specific antibodies while intracellular infections 
e.g. Afycobacterium, Leishmania, Candida require specific CDS"^  T-cells for their • 
elimination (Flynn et al., 1993; MuUer et al., 1991). Interestingly, the difference in the 
requirement of vaccination to evoke characteristic immune responses against pathogens 
may even vary against different stages of a single parasite e.g. it has been seen that the 
protective immunity required against sporozoites and liver stages of Plasmodium may be 
generated by specific CDS"*^  CTL responses (Suss and Pink, 1992) while, the blood stages 
of the parasite require CD4"^  Thl type immune response for the same without involving 
CD8^ T-cells (Vander-Heyde et al., 1993). Thus before designing a vaccine, it is 
important to keep into consideration not only the type of pathogen but the specific 
immuno-protective mechanism also that is involved in eliminating the pathogen. 
However, as suggested by Ada and Ramsay (1997) a general proposal can be made for 
vaccination that meets following requirements: 
I. The vaccine must be able to activate APCs, which involves the processing and 
presentation of antigen by the lysosomal/cytoplasmic pathways, the expression of 
co-stimulatory factors and chemokine receptors at the cell surface, and the 
secretion of certain cytokines. 
II. The vaccine formulation should enhance the replication and differentiation of T 
and B lymphocytes that leads to the generation of large pools of memory cells of 
desirable phenotypes. 
in. Vaccine preparation should include both sufficient B-cell epitopes to generate 
strong neutralizing antibody responses as well as T-cell determinants that bind 
with high affinity to at least the major regional HLA haplotypes to be recognized 
by the T-cell receptor. 
IV. The long term persistence of conformationally intact antigen is desirable, 
preferably as aggregates complexed with antibodies and held at the surface of 
FDCs (Follicular Dendritic Cells) in lymphoid tissues. This allows the continuing 
production of cells those secret antibodies of increasing higher affinity, and of 
memory B-cells. 
There are two further considerations regarding the third point as sometimes it has 
been observed that one or a few T-cell determinants in an antigen may be dominant in the 
sense that other determinants are recognized in less specific maimer this in fact forms the 
basis of the concept of immunodominance. Unfortunately, presence of these 
immunodominant determinants that appears to be of significance, may lead to escape 
recognition by CTLs if they are present in the variable region of the antigen. In such 
circumstances, it becomes important to induce responses to lesser dominant determinants 
which are present in the conserved regions of the antigen (Good, 1995). On the other 
hand, because of the phenomenon called cross tolerance, all individuals expressing an 
MHC antigen of a given specificity may not respond to a determinant that is known to 
bind strongly to that molecule (Hill, 1993). This again stresses the need for a vaccine to 
contain several T-cell determinants (Ada and Ramsay, 1997). 
The recent advances made in the fields of protein purification and recombinant 
DNA technology have led to the development of highly purified and well defined 
antigens for use in human vaccines. However, these purification protocols of vaccine 
antigens have often resulted in the elimination of intrinsic adjuvant properties, which can 
have the unwanted effect of lowering the immunogenicity of the highly purified antigen. 
The use of immunological adjuvants to enhance the immunogenicity of highly purified 
subunit vaccines and combination vaccines is a promising strategy to improve protective 
immune responses to such vaccines. Since the discovery of adjuvants, several 
preparations (natural as well as synthetic substances) have been shown to possess 
adjuvant activities as tested in experimental vaccine not only in animal models but also in 
human subjects (Vogel and Powell, 1995). 
3. Immunologic adjuvants 
Immunologic adjuvants are agents incorporated into vaccine formulations to 
enhance the immunogenicity of the vaccine antigen. Ramon serendipitously discovered 
the concept of using adjuvants to nonspecifically enhance immune response to vaccine 
antigens while he was producing diphtheria antitoxin in horses (Ramon, 1925). Since 
then, understanding of the human immune system has advanced significantly. As a result 
of which presently, adjuvant researchers are applying much of this new knowledge to 
elucidate the mechanism of adjuvant action. Hence, the most convenient way to classify 
the wide range of adjuvants includes their mode of action as mentioned below (Chedid, 
1985; Ada and Ramsay, 1997): 
I. Some adjuvants (e.g. Freund's adjuvant) form a depot of antigen for its long 
persistence primarily at the site of the application and fi-om which the antigen 
is released over a period of time that can be varied 
II. The activation and maturation of APCs, particularly DCs and macrophages, 
may be influenced by some adjuvants (e.g. liposomes) resulting in expression 
of different chemokines receptors. 
III. Many adjuvants are shown to increase the synthesis and secretion of 
enhancing factors, such as cytokines and chemokines that act principally, but 
not only on cells of the immune system, especially T and B lymphocytes. 
3.1. Properties of adjuvants 
The original mechanism of action attributed to adjuvants was the so called depot 
effect, where simple adsorption (with mineral salt) or emulsification (e.g. Freund's 
adjuvant) of an antigen increases its biologic and immunologic 'half life'. Although, this 
mechanism does play a role, however this explanation of adjuvant activity has proved too 
simplistic by itself, and it has been refined to include the improved delivery of antigens to 
APCs and to the secondary lymphoid organs. More importantly, the immunogenicity of 
synthetic peptides and various other soluble antigens that otherwise would rapidly cleared 
from the injection site without sufficient delivery to the draining lymph nodes, can be 
improved using adjuvants. In this concern some particulate adjuvants, including 
liposomes and microspheres offer a better approach of delivering antigens efficiently to 
the lymphoid system. Besides, such delivery systems can also be used to protect antigens 
from proteolytic digestion in the stomach allowing orally administered antigen to pass 
into the small intestine for delivery to the gut associated lymphoid system (Alving, 1995). 
In addition to achieve these goals, an adjuvant must be safe, it should (with 
reasonable specificity) target particular cells of the immune system, and should be stable 
and affordable. Nevertheless, the development of formulations that fiilfill all of these 
criteria is a time consuming and expensive task. Some of the currently acceptable 
adjuvants include alum that has been by far the most common adjuvant used in humans. 
Besides alum, MF59, an oil-in-water emulsion containmg squalene, has also been 
reported to be well tolerated among humans and has shown to enhance antibody 
production to antigens from HIV-1, HSV and influenza (Podda, 2001). 
Recently, a major advancement in the field of immunology has been the 
recognition that some cells of the immune system, especially antigen presenting cells 
(such as DCs) express receptors on their surfaces that recognize molecules, which are 
common to many infectious agents {e.g. bacterial LPS and lipid A) (Baldridge et al., 
2000). Such microbial components provide a danger signal to the immune system. 
Interaction of microbial products with the appropriate receptors present on APCs initiates 
the process of APC activation and maturation, and this in turn leads to a very strong T-
cell response. In this regard, bacterial DNA is of special interest because, unlike 
mammalian DNA, it contains unmethylated CpG motifs that are recognized as foreign by 
the receptors present on the APCs (Wagner H., 2001). Consequently, while bacterial 
structural components enhance both systemic as well as mucosal responses, CpG DNA is 
claimed to induce stronger immune responses with less toxicity than many other 
adjuvants (Weeratna et ah, 2000). Table 1 shows a comprehensive list of adjuvants 
evaluated for human candidate vaccines classified on the basis of their physical and 
chemical properties. 
3.2. Selection of an appropriate adjuvant for vaccination 
The ability to select from thoroughly accepted adjuvants offer vaccine formulators 
greater flexibility in the rational design of vaccines. Appropriate use of safe and effective 
adjuvants would allow significant reduction in the amount of antigen required per dose of 
vaccines, thus expanding the protective coverage of a target population using existing 
manufacturing capacity. Moreover, proper selection of an adjuvant may also aid in the 
development of novel vaccine delivery systems as well as routes of administration (such 
as transcutaneous or mucosal vaccine delivery) leading to improved vaccine compliance, 
increased efficacy, and reduction in the manufacturing and distribution costs as well. 
Unfortunately, the best known conventionally used adjuvants {e.g. alum, Saponins, 
Freund's adjuvant, LPS) loose their chance to be a-parLof. effective vaccine systems 
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either due to toxic manifestations or because of nonspecific activation of immune 
responses. Therefore, concerted efforts are coerced to develop safe and effective 
adjuvants to meet the challenges of new-generation vaccines (Gregoriadis, 1990 & 1989). 
Thus, it is important that such adjuvants should be composed of inexpensive, non-
toxic and non-immunogenic materials, should be stable on storage, biodegradable and 
preferably promote both humoral as well as cell mediated immunity. To a significant 
extent, recent advances in the controlled delivery of antigens by adjuvants and delivery 
systems (such as liposomes and microspheres) have answers to many such questions. 
Because these delivery systems would fmd particular advantages in vaccine delivery, it is 
imperative to understand the effect of controlled antigen delivery in influencing the 
outcome of an immune response. 
4. Immunological perspective of controlled antigen delivery 
The response to various vaccine antigens is routinely optimized by assessing a 
variety of delivery methods that include variation of the adjuvants and delivery systems 
used or manipulation in the dose and number of injections as well as the route of vaccine 
delivery. The recent advances in the antigen delivery have resulted in the development of 
controlled delivery systems (such as liposomes) that can offer a further parameter for 
vaccine assessment and may provide means of enhancing and manipulating the host 
immune response to a significant extent. Nevertheless, application of such delivery 
systems to vaccination would allow effective utilization of vaccine antigens that have 
previously not been able to induce adequate or appropriate immune responses thus, 
improving the responses to existing vaccines. 
4.1. Balance between immunity versus tolerance 
Early studies in fundamental immunology suggested that continuous 
administration of the antigens may lead to immunological tolerance (Dresser and 
Gowland, 1964; Mitchison, 1965). These primordial studies, however, often used 
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extremely high or low doses of antigens, poor antigenic molecules without adjuvants and 
more importantly were not aimed at determining methods of effective vaccination. 
One of the proposed mechanisms of vaccine adjuvant action as described earlier is 
the 'depot' effect that retains the antigen for an extended time period inside the body, 
allowing longer interaction of the antigen with the immune system prior to its clearance. 
Many workers have proposed that interaction time between antigen and the cells of the 
draining lymph node is one of the fundamental parameters that determine the outcome of 
any immune response (Zinkemagel et al., 1997). Moreover, the duration of longer 
antigen persistence has also been demonstrated to be the major factor which determines 
the fate of naive as well as effector T-cells e.g. naive T-cells require prolonged signalling 
for at least 20 h (lezzi et al, 1998) to 2-3 days (Zinkemagel et al, 1997) to proliferation, 
while memory T-cells require only 1 h of antigen stimulation for their proliferation (lezzi 
et al, 1998). On the other hand this prolonged stimulation may even cause tolerance 
ultimately leading to death of the effector T-cells, if continued for longer duration. In 
addition to T-cells, the activation status of APCs has been shown to be an important 
control to keep the balance between immunity versus tolerance (Th. den Boer et al., 
2001). 
While it is possible, and may be preferable to use controlled antigen delivery for 
induction of vaccine responses to overcome such situations, failures to induce immunity 
by controlled delivery have frequently occurred as a result of the inability of the delivery 
mechanism to maintain the antigen in an immunogenic form in vivo. Moreover, the 
conditions to which protein antigens are exposed during manufacturing process may 
impart some adverse effects upon antigen delivery in vivo and during in vivo degradation 
of the delivery system. Therefore, efforts have been focused on developing delivery 
systems that do not use organic solvents, high temperatures, or pH extremes during 
production, that retain the antigen in a dry state while in vivo, and that do not degrade 
into acidic by products (Li et al., 2000). In this regard, use of liposomes having inherent 
adjuvant activity may offer a better approach for antigen delivery (Alving, 1991). 
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4.2. Induction of affinity maturation and isotype switching 
The maturational changes in the immune response include antibody shift from 
IgM to a predominant IgG isotypes, development of a high affinity antibody response as 
well as presence of memory lymphocytes that will mount a rapid response following 
further antigenic challenge. This process is generally described as occurring after at least 
two doses of antigen administration. Furthermore, prolonged antigen exposure induced 
by controlled delivery systems will also allow immune maturation to occur and may even 
enhance this process many folds. This property of the delivery systems is desirable as 
most of the controlled release mechanisms result in delivery of low levels of antigen over 
time, which will first stimulate high affinity B-cell clones to proliferate. For example, 
induction of higher affinity antibody responses by low doses of antigen has been 
demonstrated (Gonzalez-Fernandez and Milstein, 1998). 
4.3. Induction of immune memory 
Research on controlled antigen delivery has facilitated the memory immune 
responses, which is the aim of most of the vaccine formulations. For example, delivery of 
Yersinia pestis V antigen through PLA microspheres as well as BSA by archaeosomes 
has resulted in generating significant memory immune responses in mice (Eyles et ah, 
2001). Apart fi-om such type of antigen delivery systems, injectable silicone implants that 
delivered avidin and IL-lb as adjuvant were usefiil in generating a strong memory 
antibody responses as well (Kemp et al., 2002). Interestingly, in these studies, the 
effector response induced a mixture of IgG 1 and IgG2 isotypes of antibodies, in contrast 
to the memory response generated by soluble antigen alone that showed predominance of 
IgGl isotype. 
Besides activating effector arms of immunity, the persistence of an antigen for 
longer duration may contribute in maintaining immune memory as well, although its 
exact role is yet to be resolved. This condition may arise due to differential antigen 
requirements of different cell types for the formation of memory cell repertoires (Eyles et 
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aL 2001; Marumaya et al, 2000). Thus, controlled antigen delivery facilitates the low 
level of antigen and continuous drainage of the antigenic materials to the FDCs present in 
the lymph nodes that eventually helps in maintaining immune memory. 
4.4. Manipulation of Thl/Tli2 responses 
Recently, it has been demonstrated that a difference in antigen exposure in vivo 
may direct different precursors to produce IL-4 secreting CD4^ T-cells (Foucras et ah, 
2000 and 2002). In contrast, some other studies performed using a range of different 
antigen delivery mechanisms have shown preponderance of both Thl and Th2 responses 
depending on the type of antigen and more importantly upon the type of delivery system 
used. For example, Moore et al., (1995) induced strong CTL responses following 
vaccination of mice with a soluble recombinant HIV protein by encapsulating the antigen 
in polymer microspheres. Similar responses were induced by delivery of ovalbumin 
releasing microspheres (Newman et al., 1998). More importantly, delivery of various 
antigens encapsulated in different types of liposomes has resulted in the induction of 
diversity in immune responses. These include a Thl dominant response following 
liposome encapsulation of various allergens (Sehra et ah, 1998), and a Th2 dominant 
response using Leishmania antigens, characterized by poor DTH responses and 
predominant IgGl antibody responses that resulted in limited protection (Afrin et al., 
2000). In absence of polarization and simultaneous induction of both Thl and Th2 
responses has also been reported from different kinds of liposomes (Krishnan et al., 
2000b; Babai et al., 1999). Hence, the rational manipulation of delivery systems, in 
combination with variation of other parameters such as dose, route of administration as 
well as use of adjuvants or delivery systems is likely to result in significant improvement 
in the effectiveness of many existing vaccines. 
Liposomes, also known for their potential and actual applications in targeted drug 
and gene delivery, appear to satisfy many of these criteria and therefore have potential for 
their future use in vaccine delivery (Gregoriadis, 1990; Allison and Gregoriadis, 1974). 
Delivery of antigens using liposomes may therefore be used to rationally manipulate the 
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type of immune response where liposomes may be tailored to obtain a desired immune 
response (Owais and Gupta, 2000). Nevertheless, various other factors including intrinsic 
properties of an antigen, booster doses etc. may play important role during elicitation of 
immune responses. Therefore, a case-by-case basis in combination with variations in 
dose, routes of administration and schedule of delivery may be trialled. The structural 
versatility of liposomes, their ability to incorporate a wide variety of antigens regardless 
of size and solubility and a favorable bio-distribution profile have rendered the system an 
effective means for the immunopotentiation and delivery of peptides and microbial 
vaccines alone or in conjunction with other co-adjuvants such as cytokines. The promise 
of the system as a vaccine carrier has recently been substantiated with the first liposome 
based vaccine (against hepatitis A) (Epaxal-Bema) licensed for use in humans (Gltick, 
1994) and by the encouraging results of phase I and phase II clinical trials with a variety 
of other liposomal vaccines (e.g. trivalent influenza, hepatitis B, diphtheria, and tetanus 
toxoid vaccines) (Gregoriadis, 1995). 
5. Liposomes as antigen delivery systems 
Liposomes were originally introduced in 1965 as models of lipid bilayer 
membrane (Bangham, 1968). Since then, they have been widely applied as models for 
studying effector phases of immune responses (Alving and Richards, 1983). In 1974, 
liposomes were proposed as carriers of antigens to augment antibody responses in vivo 
(Allison and Gregoriadis 1974). In recent years, use of liposomes as potential carriers for 
vaccines has been extensively explored (Alving 1987; Gregoriadis 1990; Alving 1991; 
Alving et ah, 1995) and applications of liposomes in immunology, and particularly those 
relating to vaccines, have demonstrated that liposomes may have considerable practical 
utility as carriers of antigens. Besides antigen delivery, liposomes have also been shown 
to serve as carriers of a variety of adjuvants and mediators, mcluding lipid A, muramyl 
dipeptide and its derivatives (Alving, 1991). 
Among the various factors involved e.g. location of an antigen either on the 
surface or encapsulated within liposomes, fluidity of the lipid bilayers, number of 
14 
lamellae (uni- vs. multilamellar), size and surface charge of liposomes have proven most 
imperative in imparting variety in immune responses in vivo. These issues have been 
reviewed extensively elsewhere (Latif and Bchhawat, 1984; Alving, 1987; Gregoriadis et 
al, 1989). 
5.1. Suitability of liposomes as vaccine carriers 
Many studies have demonstrated that liposomes can serve as effective vehicles for 
inducing humoral immunity to a wide range of liposomal antigens (Alving, 1987; 
Gregoriadis, 1990). The most common reason for using liposomes has been to convert a 
poorly immunogenic or even nonimmunogenic protein into a highly immunogenic one. 
Some investigations have reported that for certain antigens or under certain 
circumstances liposomes can be stronger adjuvants than CFA (Gregoriadis and Manesis, 
1980; Gregoriadis and Panagiotidi, 1989; Brynestad et al, 1990). Liposomes have also 
been shown to induce antibody having conformational specificities (Orgert et ah, 1990). 
e.g. an unconjugated synthetic peptide containing 25 amino acid residues was 
encapsulated in liposomes containing lipid A, and the liposomes were successfully used 
to produce MAbs that recognized widely separated sequences of amino acid epitopes 
(Geysen et al., 1984). It may be presumed from the study that this type of specificity was 
caused by the conformation of the peptide as it interacted with the liposome bilayer. 
As mentioned earlier, a considerable amount of in vitro research has demonstrated that 
interaction of certain types of liposomes containing antigens with APCs can result in the 
generation of antigen specific MHC-restricted CTLs, and the similar results have also 
been obtained in vivo (Owais and Gupta, 2001). Furthermore following immunization of 
mice with the liposomal-antigen formulation, CTL response was induced that blocked the 
formation of tumor mass from Hantaan NP transfected B16 melanoma cells in C57BL/6 
mice and delayed the growth of pre-inoculated melanoma cells (Chang et al, 2001). 
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5.2. Immunopotentiation effect of liposomes 
Immunoadjuvant properties of liposomes have been exploited with a wide range 
of antigens from bacteria, protozoa, viruses, tumors, spermatozoa, venoms and many 
review articles are available with such discussions (Allison and Gregoriadis, 1974; 
Gregoriadis, 1994 & 1990; Alving, 1991). It is now widely accepted that association of 
liposomes with the antigens either in the encapsulated form or grafted within the bilayer 
rather than a non-interacting mixture is a general prerequisite for adjuvanticity to occur 
(Therien and Shahum, 1989). Moreover, diversity in the liposomal formulations has been 
found to impart difference in immunogenicity (Gregoriadis, 1994 & 1990). 
Nonetheless, it is likely that liposomal characteristics may have to be tailored for 
individual antigen for their optimal fiinction as an immunopotentiating agents e.g. certain 
formulations of liposomes and antigen may enhance the proportion of IgG2a/2b types of 
antibodies (Phillips and Emili, 1992) while a different preparation of liposomes have 
shown to induce predominantly IgGl (Agrewala, et ah, 1996). Interestingly, the 
mechanism of liposome-induced AMI appears to be related to the fate of liposomes in 
vivo. It is likely for instance, that antibody production is partly promoted as a result of 
liposomes acting as a depot supplying antigens directly to the APCs such as macrophages 
and DCs (Velinova et al, 1996; Copland et al, 2003; Ignatius et al, 2000) at rates 
favoring its efficient processing by these cells that leads to the efficient presentation of 
the antigens. Nevertheless, migration of liposome partly to the local lymph nodes fiirther 
assists in evoking strong immune responses (Velinova et al., 1996). Besides, induction of 
cell-mediated immunity is another important feature of liposomal adjuvanticity (Alving, 
1991; Gregoriadis, 1990). Evidence to this effect includes positive delayed-type 
hypersensitivity (DTH) reactions (Manesis et al., 1979), lymphocyte proliferation assays 
(Gregoriadis et al., 1993) as well as induction of cytotoxic T lymphocytes (Owais et al., 
2001; Owais and Gupta, 2000; Reddy et ah, 1992). However, in these studies it has been 
found that liposome induced CMI is unlikely to be the result of the antigen-depot 
mechanism as demonstrated with other adjuvants including oil emulsions and alum. A 
more plausible explanation for CMI is that antigen are presented by liposomes in a 
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hydrophobic microenvironment in a way similar to that exhibited by antigen conjugated 
to a lipidic moiety. Such antigens induce DTH in proportion to the hydrophobicity of 
lipid components (Dailey and Hunter, 1977). Events leading to CMI by liposomes may 
also be favored by efficient vesicle localization in the regional lymph nodes (Tumer et al., 
1983). Moreover, recent studies on liposomal adjuvanticity at the subcellular level 
suggest that, following the localization of vesicles in liposomes, degraded liposomal 
antigen is recycled to endosomes and presented to T-cells in association with the MHC 
class II molecules (Harding et ah, 1991). It has also been demonstrated that liposomes 
engender MHC class I processing of the entrapped antigen. Apparently, this can only 
occur by employing vesicles composed of lipids that either render them unstable in the 
acidic milieu of the endosomes (Reddy et ah, 1992) or fiise with the plasma membrane of 
APCs (Owais and Gupta, 2000). Such liposomes (pH-sensitive liposomes that &se with 
the endosomal membrane or yeast lipid liposomes fusing with the plasma membrane of 
APCs) release their antigen in the cytosol of the APCs where the antigen is processed and 
presented in context of MHC class I molecules (Reddy et al., 1992; Owais and Gupta, 
2000). However, the usefulness of pH-sensitive liposomes in this respect is limited to in 
vitro systems only. It has also been suggested that a portion of the liposomal antigen 
gains access to DCs which are responsible for promoting recognition in the specific CTL 
precursors (Reddy et al., 1992). It is feasible that DCs acquire some of the antigens in 
vivo to retain it more efficiently than macrophages or, because of the increased density of 
class I MHC molecules on their surface, cells may even require relatively less amount of 
antigen for its efficient presentation (Nair et al., 1992). 
5.3. Strategies for optimization of liposomal adjuvanticity 
Approaches to further improve the immuno-adjuvant action of liposomes include 
receptor-mediated targeting to macrophages (Garqon et al., 1988), use of a variety of co-
adjuvants (Alving, 1991), modification of the structural characteristics of vesicles (Davis 
and Gregoriadis 1987) and the use of cytokines (Ho et al., 1992; Cao et al, 1992; 
Mbawiuke et ah, 1990; Abraham and Shah, 1991; Gtirsel and Gregoriadis, 1995). 
Importantly, liposomes can also been modified to target antigens to the desired APCs 
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such as macrophages and DCs. For instance, liposomes coated with a mannose-
terminating ligand promoted greater IgG responses in mice against entrapped tetanus 
toxoid than did ligand-free liposomes (Nair et ah, 1992), presumably because of 
improved targeting of vesicles to the macrophages which are known to express marmose 
receptors on their surface. Recently, the effect of targeting strategies for improving the 
interaction of liposomal PorA (a major antigen of Neisseria meningitidis) with DCs was 
investigated (Arigita et al, 2003). In this study, purified PorA was reconstituted in 
different types of targeted liposomes i.e. by using mannose or phosphatidylserine as 
targeting moieties and such targeted liposomes were found to enhance maturation of and 
IL-12 production by murine DCs. Moreover, presentation of encapsulated proteins in 
sterically stabilized liposomes to the human DCs have demonstrated to initiate CD8"^  T-
cell responses (Ignatius et al., 2000). Administration of antigens into the liposomes 
together with interleukin-2 (IL-2) has also proved to be an effective way to augment 
immune responses to a variety of antigens. These include tetanus toxoid (Gtirsel and 
Gregoriadis, 1995), bacterial polysaccharide (Abraham and Shah 1991), influenza A 
virus (Mbawiuke et al., 1990), inactivated influenza virus (Cao et al, 1992) and HSV-
recorabinant glycoprotein D (Ho et al., 1992) vaccines. 
Structural characteristics of liposomes play a decisive role (both qualitatively and 
quantitatively) in the expression of immuno-adjuvant activity (Gregoriadis, 1988). There 
are for instance, numerous studies on the extent to which membrane fluidity (Kinsky, 
1978; Gamier et al., 1991; Davis et al., 1987), number of bilayers (Shek, 1982), vesicle 
size (Francis, 1985), surface charge (Kraaijeveld, 1984), and location of antigen (Shek, 
1982; Ho et al., 1992), can affect adjuvanticity of liposome based delivery systems. 
6. Fusogenic liposomes derived from microbial lipids 
Since the inception of the concept of using liposomes as antigen carriers, 
numerous attempts have been made to develop liposome based particulate delivery 
systems. Among various strategies employed to improve liposome mediated antigen 
delivery, however, the fusogenic-liposome based vaccines remained more convincing 
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approach to deliver antigens to the proteasome machinery through membrane-membrane 
fusion with the phagolysosome membrane of the target ceils (Owais and Gupta, 2000; 
Owais et al, 2001; Reddy et al., 1991; Straubinger et al, 1985), that eventually leads to 
MHC class I mediated presentation of the antigen ensuing specific CTLs generation. One 
method for imparting fusogenicity to liposomes is to incorporate charged phospholipids 
in their preparation; thereby positively charged liposomes are capable of delivering 
encapsulated soluble antigens to the cytosol for class I MHC presentation unlike neutral 
lipid liposomes (Nakanishi et al, 1997). Moreover, apart from intrinsic fiasogenic 
property of the lipids, various glycoproteins such as hemagglutinin (HA) of influenza 
virus and fusion protein (F-protein) from Sendai virus, which are responsible for the entry 
of virus into the host cells, have also been used for imparting fiisogenicity to the 
conventional liposomes (Kunisawa et al., 2001). 
Recently, it has been demonstrated that liposomes made up of polar lipids 
extracted from Saccharomyces cerevisiae undergo membrane-membrane fiision with the 
APCs to elicit antigen specific CTL responses (Owais and Gupta, 2000; Owais et al., 
2001). Some other groups have also reported the fiisogenicity of total polar lipids unique 
to Archaea to prepare archaeosomes that can deliver entrapped solutes to the cytosol of 
the target cells. This eventually led to the elicitation of antigen specific Thl/Th2 cytokine 
as well as CD8^ CTL response against entrapped soluble antigens (Krishnan et al., 2000a 
& 2000b; Sprott et al, 1997 & 2003). 
Various strategies that have been used microorganisms to impart fusogenicity to 
the antigen delivery vehicles are as follows. 
6.1 Virosomes 
The interest to analyze the adjuvant effect of liposomes on one hand, and curiosity 
to know morphological and immunological aspects of influenza virus, on the other, led to 
the creation of the first so-called virosomes (Almeida et ah, 1975). The name itself 
reflects the structural similarities between the viral liposomes and the actual influenza 
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virus particles. The fusion potential of influenza virosome is based on the major viral 
envelop glycoprotein hemagglutinin (HA) and neuraminidase (NA) in which HA acts as a 
targeting device as it binds to sialic acid residues present on APCs and directs a passage 
for viral entry into the host cells (Skehel and Wiley, 2000; Matlin et al, 1981). After 
endocytic uptake, the acidic environment in the endosome induces a conformational 
change in the HA component of the virosomes that leads to the fusion of the virosomes 
with the endocytic membrane. Keeping in view the significance of HA conformation in 
the fusion mechanism, the protocols for influenza virosome preparation have been 
modified to conserve the properties of HA (Stegmann et al., 1987). The virosomes thus 
produced retain the receptor binding and membrane fiision activity of the native virus, by 
preserving the conformational integrity of the viral HA. These functionally reconstituted 
influenza virosomes have the capacity to deliver encapsulated macromolecules to the 
cytosol of the target cells (Bron et al., 1994; Schoen et ah, 1993). An additional 
advantage of influenza derived virosomes is that HA may also activate immune system of 
the host thereby acting as a potential adjuvant (Watts, 1997). 
The detailed in vitro studies suggests that virosomes efficiently deliver their 
entrapped material to DCs for MHC class I and class II presentation (Bungener et al., 
2002). In these studies, influenza virosomes have been shown to induce DC maturation as 
measured by upregulation of CD40, ICAM-1, B7.1 and B7.2. Moreover, insertion of HA 
as well as NA from influenza virus into immunostimulating complexes (ISCOMS) 
(Morein et ah, 1979; Coulter et al., 2003), conventional liposomes (Almeida et al., 1975), 
liposomes containing immunomodulators (Nerome et al., 1990; linuma et al., 1995) or 
liposomes having cationic lipids (Glqck and Zurbriggen, 2003), supports the notion that 
both HA and NA contribute significantly to the fusogenic properties of virosomes rather 
than envelop lipids. 
The earlier studies with influenza virosomes focused on enhancing its 
immunogenicity in vivo by using antigens from various sources. For instance, 
immunization of mice with virosomes containing a peptide derived from the influenza 
nucleoprotein (NP) resulted in successfiil priming of NP-specific CTL activity (Arkema 
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et ah, 2000). Recently, immunopotentiating reconstituted influenza virosomes (ERIV) as 
vehicles have been evaluated to deliver HLA-A* 0201-restricted hepatitis C virus (HCV) 
peptides (core 35-44 and 131-140) into the cytoplasm of at least three different target 
cell types [including T2, a transporter associated with antigen processmg (TAP)-deficient 
cell line] resulting in class I MHC presentation of the antigen and lysis by peptide-
specific CTL lines (Hunziker et al., 2002). Virosomes containing influenza matrix 
peptide 58-66 can efficiently restimulate in vivo primed CTL and importantly, IRIV 
containing HCV core peptides can even prime CTL from peripheral blood mononuclear 
cells of HCV" healthy blood donors in vitro. In another study in vivo induction of cellular 
immune responses was demonstrated against influenza virosome-encapsulated ovalbumin 
(OVA) in mice (Bungener et al., 2005). It was demonstrated that a small amount of OVA 
(0.75 ng) delivered by fusion-active virosomes was sufficient to induce strong class I 
MHC restricted CTL response. Because of their success rates, influenza virosome based 
vaccines have also been evaluated in clinical studies (Gluck, 1999). In addition to the 
observed CTL responses elicited by influenza virosomes, mcorporation of hepatitis A 
virons (HAV) in influenza-derived virosomes strongly stimulated HAV-speciflc antibody 
responses (Nerome et ah, 1990), in fact a virosomal HAV vaccine (Epaxal) is currently in 
the market as well. 
Apart from influenza, virosomes from Sendai virus have been generated by 
reconstitution of the Sendai fusion protein (F-protein), with or without the 
hemagglutinin-neuraminidase protein (HN-protein) in viral lipids (Bagai and Sarkar, 
1993 & 1994). Unlike HA & NA proteins of influenza virus, the F proteins of sendai 
virus are responsible for direct fusion with the lipid layer of the cell membrane to induce 
cell fiision (Mizuguchi et ah, 1999). It was found in earlier studies that this virus can 
efficienfly fuse with conventional liposomes as well as cell membranes at 37"C 
(Nakanishi et ah, 1985). Furthermore, the fact that the Sendai virus receptors (sialic acid 
residues) do not exist on the conventional liposome surface suggests that in the fusion 
process of Sendai virosomes this receptor is not mandatory. In addition to this unique 
fusion mechanism between the Sendai virus and liposomes, the Sendai virus-liposome 
fusion vehicle has been shown to fuse with mammalian cells (Nakanishi et ah, 1985). 
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The cytoplasmic delivery of macromolecules by these vehicles was established in vitro 
using 'diphtheria toxin A' subunit (DTA) as a probe. Sendai virus virosomes carrying 
DTA suppressed protein synthesis in cultured cells indicating its cytoplasmic delivery by 
these virosomes (Nakanishi et ah, 2000; Mizuguchi et al., 1996a). Beside their use as 
antigen delivery systems, Sendai virosome mediated delivery of anti-tumor drugs 
facilitated total disappearance of S-180 tumors from the abdominal cavity without any 
side effects (Mizuguchi et al, 1996a & 1996b). 
Further studies demonstrated that Sendai virosomes may potentially induce CTL 
response even better than complete Freund's adjuvant (CFA) (Nakanishi et al., 2000) in 
conjunction to MHC class II response for enhanced antibody production (Hayashi et ah, 
1999). Moreover, in a recent study nasal administration of model antigen (OVA) using 
fusion glycoproteins of Sendai virus on the surface of liposome membranes efficiently 
delivered antigen to antigen-sampling macrophages in nasopharyngeal-associated 
lymphoreticular tissue and elicited strong immunological responses as well (Kunisawa et 
al., 2001). In this study, such liposomes efficiently delivered the antigen into epithelial 
cells and macrophages in nasopharyngeal-associated lymphoreticular tissue and nasal 
passages. Additionally, these vesicles also facilitated an adjuvant activity against mucosal 
epithelial cells to enhance MHC class II expression as demonstrated by induction of 
OVA-specific CD4^Thl and Th2 cell responses. Furthermore, antigen-specific CTL and 
humoral response were also elicited at both mucosal and systemic sites by nasal 
immunization with these OVA-encapsulated fusogenic liposomes (Kunisawa et al., 2001). 
However in another study, primary human B and T lymphocytes (CD4'^  or CDS"^ ) and the 
human B cell line were not permissive to this kind of fiisogenic liposome-mediated 
delivery (Watabe et al., 1999). 
Apart firom these two extensively explored virosomes, reports are available where 
other viruses have been exploited to prepare fusogenic liposomes e.g. Rubella virus based 
virosomes were prepared by incorporating El and E2 envelope glycoproteins into 
liposomes (Orellana et al., 1999) and vesicular stomatitis virus (VSV) virosomes were 
generated by adding the G-protein of VSV to preformed liposomes (Loh et al., 1979; 
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Shoji et al, 2004). In addition, virosomes have also been generated using Epstein-Barr 
virus (Grimaldi et ah, 1995), human immunodeficiency virus (Comet et al, 1990), 
Semliki Forest virus (Helenius et al, 1977), Friend murine leukemia virus (Schneider et 
al, 1983), herpes simplex virus (Johnson et ah, 1984) and Newcastle disease virus 
(Kapczynski and Tumpey, 2003) etc. However, ftision activity of these virosomes was 
not always determined and the main emphasis of using such vehicles remained restricted 
to study induction of humoral responses against the specific viruses from which they 
have been derived. 
6.2 Archaeosomes 
Liposomes prepared from polar archaebacterial glycerolipids (archaeosomes) 
have been shown to induce strong adjuvant action in mammals. Membranes of 
archaebacteria are reported to contain lipids that are chemically distinct from that of 
eukaryotic or other prokaryotic organisms. The saturated, branched C-20, C-25 and C-40 
phytanyl chains form liposomes with unique properties in context to physical and 
chemical stability and uptake by APCs (Patel and Sprott, 1999) and it was speculated that 
such properties of lipids are the possible factor for observed adjuvanticity to occur (Sprott 
et al., 2004). Immune responses comparable to immunization with CFA and superior to 
conventional liposomes have been reported after immunization with archaeosomes 
(Krishnan et ah, 2000b; Conlan et al, 2001). Authors have shown the potential of 
liposomes composed of archaebacterial lipids of various archaebacteria in evoking CTL 
as well as antibody responses to their entrapped antigens (Krishnan et al., 2000a; 2001 & 
2003). In these studies, ether glycerolipids extracted from various archaebacteria were 
formulated into liposomes and mice of varying genetic backgrounds, immunized via 
various parenteral routes with archaeosomes containing BSA demonstrated markedly 
enhanced serum anti-BSA antibody titers. These titers were often comparable to those 
achieved with CFA and considerably more than those with alum or conventional 
liposomes (PC/PG/chol, 1.8:0.2:1.5 molar ratio). Furthermore, antigen-specific IgGl, 
IgG2a, and IgG2b isotype antibodies were all induced. Apart from BSA, encapsulation of 
OVA or hen egg lysozyme within archaeosomes showed similar immune responses 
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(Krishnan et al., 2000b). Moreover, antigen-archaeosome immunizations induced strong 
cell-mediated immune response as evident from antigen-dependent proliferation and 
substantial production of both Thl (IFN-7) as well as Th2(IL-4) cytokine responses. In 
contrast, conventional liposomes induced little cell-mediated immunity, whereas alum 
stimulated IL-4 response only. Further, in contrast to alum and CFA, archaeosomes 
composed of Thermoplasma acidophilum lipids evoked memory antibody responses to 
the encapsulated antigen as observed at == 300 days after two initial immunizations (days 
0 and 14). The observed response was shown to be correlated with increased antigen-
specific cell cycling of CD4^ T cells as revealed by flow cytometry. In further studies, a 
comparison between liposomes prepared from the lipids extracted from archaebacteria 
Haloferax volcanii, Planococcus sp. and a eubacterium Bacillus flrmus was made on 
their ability to mfluence immune system to evoke effective immune responses (Sprott et 
al., 2004). It was hypothesized that occurrence of isoprenoid neutral lipids was the 
possible factor for the adjuvanticity of B. flrmus crude lipid-SDS micelles. On the other 
hand, due to similarities of lipid head groups (predominantly PG lipids, sulfoglycolipids 
and cardiolipin) between H. volcanii and Planococcus spp., either kind of vesicles 
delivered their encapsulated antigens in vivo to both MHC class I and class II 
compartments of APCs. Interestingly, out of these three liposome formulations, 
archaeosomes promoted a greater memory recall antibody responses in immunized mice 
that were found to be highly significant as compared to Planococcus liposomes. 
Surprisingly, CTL response generated by Planococcus liposomes were of short term, 
while liposomes made up of lipids from H. volcanii consisting of almost same lipid 
composition, elicited sfronger CTL response. Moreover, Planococcus liposomes led to 
the activation of DCs to secrete inflammatory cytokines (IL-12 and IL-6) that may be the 
possible reason for observed short-term CTL responses (Dudani et al., 2002). In other set 
of experiments, liposomes made up of archaeal lipids from M. smithi enhanced 
costimulation on DCs to facilitate T-cell activation (Krishnan et ah, 2001). However, the 
response was independent of IL-12 production (Krishnan et al, 2003), which supports 
the adjuvant activity of archeal lipid liposomes by providing both signals required to 
activate T-cells: efficient antigen delivery as well as co-stimulation (Zinkemagel, 2002). 
Furthermore, archaeosome-enfrapped listeria antigen elicited rapid and prolonged 
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specific immunity against L. monocytogenes in the mice model (Conlan et ah, 2001). In 
this regard, superiority of tested archaeosomes to conventional liposomes (made up of 
PC/PG/chol) further emphasizes significant contribution of unique features of 
archaeosomes in antigen delivery. 
In the context of the lipid vesicles, possible routes of their entry into the cell 
include either direct fusion with the plasma membrane or phagocytosis by APCs (Owais 
and Gupta, 2000). Alternatively, some other routes like endocytosis mediated by 
mannose receptor, FcRs, and those recognizing apoptotic cells, like PS-specific receptors, 
may be responsible for their uptake (Somersan and Bhardwaj, 2001; Li et al., 2003). 
Inspite of several reports available on archaeosome mediated antigen delivery, no 
intercession has been developed towards the fusogenicity of these liposomes. Information 
deciphering the exact mechanism of archaeosome uptake by APCs was behind the screen 
until recently; an article demonstrating role of PS in uptake of such liposomes by APCs 
suggests that the whole process is dependent on phosphatidylserine receptor present on 
macrophages and DCs (Gumani et al., 2004). Archaeosomes from M. smithii have been 
fully characterized and found to comprise of 30 mol% of the archaetidyl, which is 
equivalent of PS (Sprott et al., 1999). These types of liposomes are striking in forming 
archaeosomes with surface-exposed PS head groups (Sprott et ah, 2003). Hence, antigen 
presentation results corroborate PS-specific recognition as triggering archaeosome entry 
into the phagosomal compartment, leading to antigen delivery for MHC class I (Gumani 
e? a/., 2004). 
6.3 Yeast lipid liposomes 
An interesting correlation between the plasma membrane lipid composition of the 
living organisms and their generation time can be made. For example, bacteria such as 
Escherichia coli. Bacillus megaterium and Bacillus subtilis have preponderance of 
anionic lipids viz. PG and DPG (in combination of PE) in their plasma membranes and 
have very short generation time of the order of 20-25 minutes (Rattray, 1988; Jain, 1988). 
On the other hand, membranes of relatively more evolved Saccharomyces cerevisiae or 
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Candida albicans have greater variety of phospholipids with lower percentage of anionic 
lipids (e.g. PG, PI, PS, DPG) and the organisms have a generation time of approximately 
two hours. Since both the classes of organisms multiply by binary fission, it can be 
presumed that the presence of anionic lipids facilitates the fusion of the membranes 
essential for high duplication rates (Owais and Gupta, 2000). Unlike the lower organisms, 
the more evolved eukaryotes have neutral phospholipids as major membrane components 
and have generation times of the order of days (cf. ~22 hrs). The plasma membrane of 
lower organisms is mainly composed of amino phospholipids along with cardiolipin and 
PG. The eukaryotic plasma membrane lipid composition is different from that of lower 
organisms and earlier work revealed the composition and distribution of phospholipids in 
eukaryotic cells (Kumar and Gupta, 1983). They contain all classes of phospholipids, 
distributed in a set fashion in the two leaflets of the bilayer. The amino-phospholipids are 
mainly confined to the inner leaflet and play a major role in exocytosis, which involves 
membrane-membrane fusion. 
In the earlier studies, it was demonstrated that asymmetric distribution of 
phospholipids is also maintained in yeast cells (Balasubramanian and Gupta, 1996; Dixit 
and Gupta, 1998). However, similar to other lower organisms the backer's yeast 
(Saccharomyces cerevisiae) undergoes rapid cell duplication, in which the two opposite 
sites of the plasma membrane inner leaflet come close to each other and fiise under 
physiological conditions. Therefore, the flisogenic properties of the vesicles formed from 
yeast lipids were evaluated to deliver antigen to APCs (Owais and Gupta, 2000). In this 
study, the fusion efficiencies of various types of membrane vesicles were compared using 
epifluorescence as well as other conventional membrane-membrane fusion assay methods. 
In the content mixing assay, marked decrease in fluorescence results when ANTS 
containing fusogenic vesicles (yeast lipid liposomes) fuse with the excess of DPX 
containing vesicles of same lipid composition. Among various types of vesicles used in 
this study, quenching of fluorescence was highest in yeast lipid liposomes indicating their 
sfrong fusogenic potential. 
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In further extension of the work, it was demonstrated that yeast lipid liposomes 
deliver entrapped model antigen (OVA) to the cytosol of the APCs for eliciting effective 
CTL responses whereas OVA encapsulated in conventional egg PC/chol liposomes or its 
emulsion with IFA failed to induce that levels of immune responses (Owais et al., 2001). 
While, the conventional liposomes predominantly polarize immune response biased 
towards Th-2 type, as evident from the enhanced secretion of IL-4 and IgGl isotype of 
antibody (Agrewala et al., 1996), fusogenic liposomes made up of yeast lipids were 
found to evoke a mixed (Th-1 & Th-2) type of responses with Th-1 type somewhat 
predominates with the multiple doses of immunization (Owais et ah, 2001). A higher 
degree of humoral response was also observed after immunization with yeast lipid 
liposome containing antigen. This interesting difference in the elicitation of immune 
responses using various lipid vesicles is of immunological significance and is attributed 
to the fusogenic property of the lipids. The membrane lipid composition of yeast exhibits 
a great majority of anionic phospholipids (PC 48.1; PE 23.1%; PI 16.1%; PS 6.0%; PG 
3.9%; and cardiolipin 1.6%) that play pivotal role in membrane-membrane fusion. Like 
yeast. Bacillus subtilis contains majority of anionic lipids m their plasma membrane 
(mainly PG & PE) and have a short generation period (Rattray, 1988). Recently, 
membrane lipids from B. subtilis were extracted to demonstrate their fusogenic potential 
(Deba et ah, 2005) that were found to posses greater fusogenicity than erythrocyte 
vesicles (RSO and ISO) or conventional egg PC/choI vesicles as revealed by 
conventional fusion assays. Moreover, to reconfirm that such vesicles interact via 
membrane-membrane fusion as a major mode of interaction with the target cells (J774 
A.l cells), the toxic effect of 'ricin A' was observed by incubating J774 Al cells with 
'ricin A' loaded vesicles. It was shown that effect of 'ricin A' is more remarkable in case 
of subtilosomes followed by ISO and RSO erythrocyte vesicles (Deba et ah, 2005). 
Therefore, both yeast lipid liposomes as well as subtilosomes (liposomes made up of 
Bacillus subtilis lipids) offer a novel approach to deliver the entrapped antigen into the 
cytosol of the APCs. 
Apart from these fusogenic liposomes used as antigen delivery vehicles, few 
reports are available on fusogenic vesicles that belong to other classes of vesicle family 
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(e.g. niosomes, transferosomes, proteosomes etc.). Niosomes are small unilamellar 
vesicles made from non-ionic surfactants. Hence, they are also called non-ionic surfactant 
vesicles (NISV) (Brewer and Alexander, 1994) or Novasomes (Gupta et al, 1996). BSA 
entrapped within niosomes was reported to be as immunogenic as BSA with CFA 
(Brewer and Alexander, 1992) and the chemical stability of niosomes is higher than the 
stability of conventional phospholipid liposomes. Transfersomes are 'ultra deformable' 
liposomes with enhanced skin penetrating properties. These vesicles consist of 
PC/cholate (9:2 molar ratio). Studies with model antigen have shown that transfersomes 
have an upper hand than conventional liposomes when administered epicutaneously (Paul 
and Cevc, 1995). Cochleates are another exception in the liposome group because they 
are non-vesicular bilayer sheets consisting of PE/PS/chol. Calcium ions are added which 
intercalate with the bilayers. This results in a rolled up bilayer sheet without internal 
volume. Results obtained with protein- and DNA-cochleates have been reviewed 
elsewhere (Gould-Fogerite et ah, 1998). Proteosomes are also considered as outsiders in 
the liposome group as they are comprised of protein mainly. These vesicles are of 
bacterial origin (outer membrane) and are prepared by solubilization of bacterial 
membranes, followed by ammonium sulphate precipitation and dialysis against detergent 
containing buffer (Lowell et ah, 1988). Electron micrographs revealed that these vesicles 
have a size of about 100 nm, but the protein: lipid ratio is higher than can be achieved 
with purified protein incorporated in liposomes. Proteins and peptides are non-covalently 
complexed to the proteosomes, making them highly immunogenic (Lowell et ah, 1997). 
Moreover, fusogenic liposomes have been prepared from artificial lipid membranes 
consisting of synthetic arenavirus 'ftision peptide' (Glushakova et al., 1992). In addition, 
it has been demonstrated that non-phospholipid liposomes composed primarily of 
dioxyethylene acyl ether and cholesterol have capacity to fuse with membranes 
composed primarily of phospholipids (Baraka et ah, 1996). 
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1. Introduction 
Apart from providing a boundary to the cell, plasma membrane plays many 
important biological functions (Voet et al., 1999). Several evidences advocate that the 
composition of membrane is crucial for various physiological activities that rely on 
membrane-membrane fiision viz., fertilization, phagocytosis, exocytosis, and cell division 
etc. (White, 1992; Voet et ah, 1999). In fact, the membranous organelles present in the 
cytoplasm are part of a dynamic network where molecules are shuttled back and forth 
from one part of the cell to another. Most of these shuttling pathways involve the process 
of membrane-membrane fiision. For instance, the secretory or exocytic pathways in 
which materials are synthesized in endoplasmic reticulum or Golgi complex, and are 
transported to various destinations like plasma membrane, lysosomes or vacuoles etc. and 
the endocytic pathways, which operate in opposite direction where materials move from 
exterior of the cell to sub-cellular compartments such as endosomes or lysosomes 
(Andrews and Johnson, 1996; Emr and Malhotra, 1997). 
Many investigations regarding the mechanism and regulation of vesicular 
transport have been put forth in cell free systems to emulate inter-compartmental 
transport (Vidal and Hoekstra, 1995). Most of these studies suggest that biological 
molecules such as proteins and nucleotides take active part in the distinct interaction 
steps that are crucial for various transport events (Sztul et ah, 1992; Takizawa et al., 1993; 
Pley et al., 1993). Furthermore, intracellular trafficking is governed by heterotrimeric G-
proteins, SNAP, NSF, and SNARE etc. (Sollner et al., 1993). Present studies on the 
molecular events involved in the membrane-membrane fusion, remain focused on the role 
of proteins in the process. In contrast, no efforts have been made in the direction of 
revealing involvement of lipid counterparts in the fusion events. Inspite of the fact that 
proteins determine the specificity of biomembrane fusion, their role in the induction of 
membrane fusion is doubtful. This could be justified on the premise that the central event 
during membrane fusion is the merger of two membranes which requires a transient 
reorganization of membrane lipids into highly curved fusion intermediates. Importantly, 
the local-point fiision concept also applies to pure lipid model membrane fusion, where 
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^iectron micrographs revealed the presence of very small fusion intermediates 'lipid 
particles', suggestmg a common lipidic intermediate in model and biological membrane 
fusion (Verkleij et al., 1979; Verkleij, 1986). The fact that membrane fiision is a local 
point event implies that fusion events also require a local restructuring of the interacting 
lipid bilayers, and that relatively few lipid molecules (hundred to a few thousand), are 
directly involved in the fusion process. Moreover, the marked variation in lipid 
compositions of the primitive and evolved organisms on one hand, and energy driven 
intricate mechanisms operative in the maintenance of membrane lipid asymmetry in 
higher eukaryotes on the other, suggests the important role of lipids in various membrane 
related processes {cf. membrane-membrane fusion). For example, the asymmetric 
distribution of lipids between two leaflets of the plasma membrane of erythrocytes is 
quite apparent, where outer leaflet contains the bulk of sphingomyelin and PC (both 
bilayer forming neutral lipids) while the inner leaflet has preponderance of PS, PI and PE 
(Sollner et al. 1993; Williamson et al, 1985; Kumar and Gupta, 1983). 
1.1. Molecular models of membrane fusion 
Membrane fiision requires close apposition and coalescence of a small area of the 
lipid bilayers. A progressive force is required to drive two bilayers closer than 3 nm 
together (Helm and Israelachvili, 1993). According to the proposed models, at the 
membrane fusion site, two forces dominate, a repulsive hydration force arising from 
water tightly bound to the lipid headgroups, and an attractive hydrophobic force between 
the hydrocarbon interiors of the membranes. At a pressure of about 100 atm, the 
attractive hydrophobic force locally bypasses the repulsive hydration force resulting in 
the semi-fusion of the bilayers. Introduction of membrane defects exposes more of the 
membrane interior and substantially reduces the pressure required for semi-fiision. This is 
likely to be a general theme in most of the membrane fusion events. During biomembrane 
fusion, defects in membrane lipid packing could arise from extreme membrane curvature, 
local changes in lipid composition, or the insertion or de-insertion of a stretch of 
hydrophobic amino acids (Blumenthal et al, 1998; White, 1992; Bentz, 2000). 
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With few exceptions (Shangguan et ah, 1996; Bonnafous and Stegmann, 2000), 
membrane fusion is envisaged as a 'non-leaky' process that involves three distinct stages: 
membrane adhesion, semi-fusion, and pore formation (figure 1). At the semi-fusion stage 
of membrane fusion, the outer (cis-) lipid monolayers of the two membranes are 
continuous but the inner (trans-) lipid monolayers are still separated. Experimental 
support for the existence of a semi-fusion intermediate in both model and biological 
membrane fiision has been obtained (Lentz and Lee, 1999; Razinkov et al., 1999). Two 
main molecular models have been proposed for the semi-fusion intermediate. In both 
models, the semi-fusion intermediate has a strong net negative (concave) monolayer 
curvature. In the first model, two membranes join to form an inverted lipid micelle at the 
semi-fusion stage (Verkleij, 1984), while the second, and currently prevailing model, 
predicts the formation of a so-called stalk (Markin et ah, 1984). In a modification of the 
stalk model (Siegel, 1993 & 1999), the stalk develops into a trans-monolayer contact, 
which is short-lived and ruptures resulting in the formation of a small pore (figure 1). It is 
important to note that the evaluation of the different models of membrane fusion is 
dominated by theoretical considerations, and that direct data on the structure and 
composition of the fusion intermediates (in the end in biomembrane fusion) are 
absolutely required before a definite answer concerning the molecular nature of the semi-
fusion intermediate can be given. Nonetheless, the stalk mechanism is compatible with a 
wide range of observations on model membrane fusion, and there is increasing evidence 
that similar intermediates, with a net negative monolayer curvature, mediate 
biomembrane fiision (Chemomordik, 1996). 
1.2. The role of lipids in biomenibrane fusion 
As revealed by patch clamp analysis, the early fusion pore is often seen to be 
reversibly open and close several times. Evidences suggest that in the formation of initial 
transient pore, lipids are likely to play a key role in the induction of biomembrane fusion 
for several reasons (Monck and Fernandez, 1996; Lindau and Aimers, 1995). Firstly, 
proteins are not an absolute prerequisite for membrane fusion; pure lipid model 
membranes can be induced to fiise in the absence of added proteins. Secondly, important 
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Figure 1: Stalk model for the intermediate stages during membrane fusion'. 
Adhesion (A), semi-fusion (B), and pore-formation (C). 
Semi fusion starts with the formation of a stalk (B-1), which develops into atrans-
monolayer contact (B-2). At the semi-fusion stage of membrane fusion, the outer 
(cis) lipid monolayers of the two membranes are continuous but the inner (trans) 
lipid monolayers are still separated. Hydrophobic interstices are shaded. (Siegel, 
1993 & 1999). 
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characteristics of biomembrane fusion such as capacitance flickering are also observed in 
pure lipid model systems, and the activation energies of the molecular rearrangements 
involved appear to be very similar (Lee and Lentz, 1998). Finally, low (sublytic) 
concentrations of lysolecithin (LPC) have shown to inhibit model membrane as well as 
biomembrane fusion in an efficient and reversible manner. This activity of LPC was also 
observed in biological systems as different as the low pH-induced fusion of virus-infected 
cells, and exocytosis in patch-clamped mast cells or isolated sea urchin cortices 
(Chemomordik, 1996). 
Hence, all these examples especially the latter suggests that both model and 
biological membrane fusion events involve a lipidic intermediate with a net negative 
monolayer curvature. Together, these findings support the notion that the membrane lipid 
composition is an important determinant of the willingness of a membrane to fuse, and 
suggest that specific lipid species may play an active role in the local destabilization and 
fusion of the membranes. For example, it was demonstrated earlier that LPC, a micelle-
forming ('type-I') lipid, was involved in biomembrane fusion (Lucy, 1978). However, 
recent data have shown that lysophospholipids do not stimulate but inhibit model and 
biological membrane fusion. Moreover, acidic phospholipids, especially phosphatidic 
acid (PA) and phosphatidylserine (PS), have also been proposed to play a central role m 
the induction of biomembrane fusion but in conjunction with Ca^"*^  (Papahadjopoulos et 
al, 1990). 
On the other hand, inverted non-bilayer-preferring lipids ('type-II lipids') have 
been proposed to play a key role in biomembrane fusion (Verkleij et ah, 1979). In 
contrast to type-I lipids, which are virtually absent fi-om biomembranes, type-II lipids are 
present in significant amounts in almost every biomembrane (De Kruijff e? al., 1985; 
Epand, 1998). One of the non-bilayer lipid phases formed by these lipids is the inverted 
hexagonal-II (Hn) phase. Almost any biological membrane contains lipids that upon 
isolation will form a Hn-phase under physiological ionic strength, pH and temperature. 
Examples are the unsaturated phosphatidylethanolamines (PEs) present in all eukaryotic 
membranes (in the plasma membrane, typically 25 mol% of total phospholipid, of which 
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80% is present in the cytosolic leaflet). The lipid molecules in the Hn-phase are organized 
in hexagonally arranged cylinders, with the polar headgroups lining a central aqueous 
channel (figure 2). The tendency of type-II lipids to form inverted non-bilayer lipid 
structures can be explained by considering their overall dynamic shape (Israelachvili et 
ah, 1980; Cullis et ah, 1986). While, 'type-II lipids' are cone-shaped; they have a small 
headgroup area as compared with the cross-sectional area of the acyl chains, 'type-I' 
lipids, such as most lysophospholipids, have an inverted cone shape, while bilayer-
preferring lipids are best described as having the shape of a cylinder. 
The type-II lipids are forced to remain in the lipid bilayer, in a situation which is 
often referred to as 'frustration'. In prokaryotes where the lipid composition of the 
membrane can be easily manipulated, the ratio of bilayer to non-bilayer preferring lipids 
was shown to be under strict metabolic control, indicating that propensity of the 
membrane to form 'type 11' structures is of great importance for their cellular functions 
(Rietveld et ah, 1993; Osterberg et at, 1995). Interestingly, the total lipid extract of 
several biological membranes forms an Hn-phase upon hydration, suggesting that, in vivo, 
these membranes will be eager to form non-bilayer lipid structures such as those involved 
in membrane fusion. Thus, it can be presumed that the willingness of a biomembrane to 
fuse may partly be determined by the ratio of bilayer to non-bilayer-preferring lipids 
present in the membrane. Most of the biomembranes contain large amounts of type-II 
lipids on one hand, and a correlation exists between their presence and membrane fusion 
activity in model systems on the other. This leads to the conclusion that type-II lipids are 
attractive candidates for a direct involvement in biomembrane fusion. By virtue of their 
low headgroup hydration, type-II lipids would be expected to enhance membrane 
adhesion by reducing the hydration repulsion, while their negative curvature preference 
should facilitate the formation of highly curved concave semi-fusion intermediates and 
stimulate membrane fusion. The idea that biomembrane fusion may take advantage of the 
phase-preference of type-II lipids is supported by studies on the lipid dependency of 
biomembrane flision. 
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Figure 2: Shape-structure concept of lipid polymorphism. 
Unsaturated fatty acids, ceramide, diacylglycerol and cholesterol do not 
themselves form Hn phase, but promote Hn phase formation in mixed-lipid 
systems. (Israelachvili et al, 1980; Cullis et al., 1986) 
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2. Scope and plan of the present study 
A difference has been observed between the lipid compositions of eulcaryotic and 
prokaryotic plasma membranes. While the prokaryotic plasma membrane (e.g. in bacteria 
) is mainly composed of amino-phospholipids along with cardiolipin and 
phosphatidylglycerol (Rattray, 1988; Krishnan et al, 2000a), eukaryotes contain all 
classes of phospholipids distributed in the outer as well as inner leaflets of the bilayer, 
where the amino phospholipids are mainly confined to the inner leaflet and play a major 
role in exocytosis, which involves membrane-membrane fusion (Voet et al., 1999). The 
unique lipid composition in lower organisms could be a strategy to cope with the high 
multiplication rate of the microbes, as such lipids facilitate the fusion of the two opposite 
sites of inner leaflets (e.g. due to Ca^ ^ binding) under physiological conditions and earlier 
studies revealed the fusion potential of lipids from Saccharomyces cerevisiae (backers 
yeast) (Owais & Gupta, 2000). Similar to the other lower organisms {e.g. yeast), 
membrane lipid composition of Escherichia coli exhibits a great majority of anionic 
phospholipids that may play a pivotal role in membrane-membrane fusion (Pluschke and 
Overath, 1981). Hence, the aim of the present study was to find out the fusogenicity of 
liposomes made up of E. coli lipids (escheriosomes) and their ability to deliver the 
entrapped molecules to the cytosol of the target cells. 
In the present study, fusogenic properties of E. coli lipids are demonstrated 
employing routine membrane fusion assays. The liposomes comprised of lipids extracted 
from Escherichia coli (escheriosomes) were found to fuse with the plasma membrane and 
thereby successfully deliver encapsulated substances to the cytosol of the target cells. 
3. Material and Methods 
3.1. Chemicals and reagents 
EPC was prepared using the standard method as described previously (Singleton, 
et al. 1965). Cholesterol (chol) was purchased from Centron Research Laboratory, 
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Bombay, India, and crystallized three times with methanol prior to its use. Calcein was a 
kind gift from Dr. G. C. Varshney (IMT, Chandigarh, hidia). Peptone and yeast extract 
were from Hi Media Laboratories (Bombay, India), while dexfrose was from S.D. Fine 
Chemicals (Boisar, India). Dulbecco's modified Eagle medium (DMEM), Hanks balanced 
salt solution (HBSS) and foetal bovine serum were obtained from Life Technologies 
(Grand Island, NY, USA). Lysozyme (chicken egg white), deglycosylated ricin A, 
Imidazole, PercoU, Sephadex G-50, Sepharose 6B, and EDTA were all from Sigma 
Chemical Company (St Louis, MO, USA). L-Aminonapthaline-3,6,8-trisulfonic acid 
(ANTS) and iV,A -^/7-xylylenebis (pyridinium bromide) (DPX) were bought from 
Molecular Probes, Inc. The fluorescent probes, L-(phophatidylethanolamine-iV-(4-
nitrobenzo-2-oxa-l,3-diazole) (NBD-PE) and 7V-(lissamine rhodamine B sulfonyl) 
phosphatidylethanolamine (Rh-PE) (Avanti polar lipids) were a kind gift from A. Puri 
(NIH, Frederick, MD, USA). ['^ ^IJSodium iodide (carrier free) and [^^S]L-methionine 
were bought from Bhabha Atomic Research Center (Trombay, India). Lysozyme was 
radio-iodinated as previously described (Fraker and Speck, 1978). The amount of protein 
entrapped in the liposomes was determined using the bicinchoninic acid protein assay 
(Pierce Chemical Company). J774 A.l, a macrophage cell line, was purchased from 
American Type Culture Collection (Rockville, MD, USA) and was grown in DMEM (pH 
7.2) containing L-glutamine (4 mM), sodium pyruvate (110 mg-L" )^, penicillin (100 
U-mL''), streptomycin sulfate (100 ng-mL"') and sodium bicarbonate (3.7 g-L"') in 75 mL 
culture bottles (Costar, MA, USA) at 37 °C, under 7.5% CO2. 
3.2. E. coli lipids 
E. coli K12 was cultured in nutrient broth (1% peptone, 0.3% beef extract, 0.3% 
yeast extract and 1% sodium chloride; pH 7.4). The cells were harvested from mid-log 
phase (18-20h). Phospholipids were isolated by the method of Bligh-Dyer, as modified 
by Kumar and Gupta (1983). The lipid composition was determined as described 
previously (Kumar and Gupta, 1983) and found to be as follows: 
phosphatidylethanolamine, 82 ± 1.2; phosphatidylglycerol, 13.8 ± 0.8; cardiolipin, 4.2 ± 
0.6. 
3.3. Lipid vesicles 
Large unilamellar vesicles (LUVs) were prepared essentially by the freeze-thaw 
method as described previously (Hayward et al., 1985). The outer diameter of these 
vesicles was =*= 160 ± 50 nm as revealed by electron procroscopical method. LUVs for 
RET experiments were formed using E. coli lipids (or EPC/chol), NBD-PE and Rh-PE in 
a molar ratio of 98.4 : 1 : 0.6 . For the aqueous content mixing experiments, which 
involves the fusion of two different types of liposomes, LUVs were prepared by hydrating 
E. coli lipids or EPC/chol (15 i^mol lipid) with 1.5 mL of 10 mM Tris/HCI (pH 7.5), 
containing ANTS (25 mM) and NaCl (40 mM) or DPX (90 mM). The entrapped ANTS 
(orDPX) from free ANTS (or DPX) was separated by gel filtration using a Sephadex G-
50 column. 
Dried reconstituted vesicles (DRVs) were formed as described previously (Kirby 
and Gregoriadis, 1984). Finally, free flowing, lyophilized, dried powder was re-hydrated 
with distilled water and reconstituted in phosphate buffer saline (IM PBS, pH 7.2). The 
preparation was centrifiiged at 14 GOOx g and the pellet was washed at least three times 
with PBS to remove traces of the un-entrapped solute. 
3.4. Erythrocyte membrane vesicles 
Erythrocytes from fresh human blood were isolated by removing the plasma and 
buffy coat. The cells were lysed by treating with lysis buffer and then resealed after 
washing three times with the isotonic PBS as described elsewhere (Williamson et al., 
1985). The prepared erythrocyte membrane vesicles were then pelleted at 1200x g (15 
min, 4 °C). After washing several times, the preparation was resuspended in PBS for 
fiirther use. 
3.5. Resonance energy transfer (RET) assay 
The lipid mixing between the NBD/rhodamine-Iabeled E. coli lipids (or EPC/choI) 
LUVs (= 600 nmoles lipid) and unlabeled E. coli lipid (or EPC/chol) LUVs was followed 
by monitoring RET (Struck et al, 1981) between NBD (absorption, 470 nm; emission, 
520 nm) and rhodamine (absorption, 536 nm; emission, 585 nm). The excitation wave 
length was chosen to be 20 nm below the absorption maxima of NBD so as to allow a 
better resolution between the scattered light peak and the NBD emission peak, and also to 
minimize the direct excitation of rhodamine. Finally the fluorescence was monitored at 
520 nm. The efficiency (E) of RET was calculated as follows: 
E=\ - F/Ft where 'F ' is the NBD fluorescence in the presence of rhodamine, and 
'Ft' is the NBD fluorescence at maximal dequenching, which was measured after 
disrupting the vesicles with Triton X-100 (1% final concentration). 
3.6. Aqueous contents mixing assay 
Quenching of the ANTS fluorescence by DPX was observed in order to follow the 
mixing of the aqueous contents of the vesicles undergoing fusion (Ellens et al., 1985). 
The ANTS-containing LUVs were mixed with a 10-fold excess of the DPX-containing 
LUVs in a total volume of 3 mL. The mixture was incubated at 37 °C and the ANTS 
fluorescence was measured at varying periods of time. The ANTS fluorescence observed 
at zero minute was taken as 100% fluorescence, while the fluorescence values taken after 
lysing a mixture of ANTS-containing and DPX-containing LUVs with Triton X-100 (1% 
final concentration) were taken as 0% fluorescence. The excitation and emission 
wavelengths used were 380 nm and 540 nm, respectively. 
3.7. Macrophage-escheriosomes interaction 
The interaction of the macrophages with the escheriosomes was observed by 
transfer of fluorescently-labeled membrane markers fi-om the vesicles to the macrophages. 
Membranes of liposomes were either fluorescently labeled by incorporating NBD-PE (5 
mol %) in either types of vesicles (EPC/chol or E. coli lipid liposomes). The J774 A.l 
cells (1 X 10 )^ were cultured overnight on a sterile cover slip in complete DMEM medium 
containing 10% foetal bovine serum. The cells were washed with incomplete DMEM and 
incubated at 4 °C for 2 h. After washing once with incomplete DMEM, the cells were 
then pulsed with NBD-labeled liposomes (600 nmol lipid) for 60 min in incomplete 
DMEM (FBS free) at 37 °C. The fixed macrophages were observed under a Leitz 
fluorescence microscope at 100 x magnification, using an 13 filter. 
3.8. Intracellular localization of lysozyme 
DRVs loaded with '^^I-labeled lysozyme (== 4 x 10^  c.p.m.-mg protein"') were 
used in these experiments. J774 A.l cells (5 x 10^  cells-well"') were cultured in six-well 
plates and incubated for 1 h at 37 °C with lipid vesicles. The cells were washed with PBS 
followed by fixation with 1% paraformaldehyde solution. The cells were then detached 
off the culture plates using chilled Versene solution. Finally, to determine the intracellular 
distribution of labeled lysozyme, the cells were broken by a nitrogen cavitation method 
using a Parr bomb(Wileman et ah, 1984) before centrifuging them at 750x g for 15 min. 
The supernatant was flirther centrifiiged at l,00,000x g for one hour at 4 °C using 
Beckman L8-55 M ultracentrifuge. The pellet was suspended in 3.0 mL of imidazole 
buffer (3 mM imidazole, 0.25 M sucrose; pH 7.4), and then fractionated into the plasma 
membrane/nucleus, cytosol, endosome/lysosome, and other organelles. The purity of each 
fraction was determined on the basis of enzyme marker assays, as described previously 
(Wilemane^a/., 1984). 
3.9. Inhibition of protein synthesis in the macrophages by 'ricin A' 
J774 A.l cells (1x10^ cells-well"') were cultured in a 24-well plate overnight at 
37 °C. Next day cells were incubated separately with three different forms of the toxin 
viz.; free 'ricin A', 'ricin A' encapsulated in EPC/chol DRVs or 'ricin A' encapsulated in 
E. coli lipid DRVs at 37 °C for 1 h. The cells were washed, and then pulsed with [^ ^S]L-
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methionine (1 ^Ci•wel^') in a total volume of 200 ^L•welr' for 2 h at 37 °C. The cells 
were washed twice with DMEMand were treated with 7 M guanidine (50 ^L-well''). The 
final volume was made up to 200 nL-well'' with PBS. The suspension was vortexed, and 
small aliquot (20 ^ L) firom the cell lysate was withdrawn in eppendorff tubes. The lysate 
was treated with trichloroacetic acid (25%, 100 \iL) and BSA (1%, 50 \iL) and then 
centrifuged. The precipitate was washed once with 10% tricholoroacetic acid and counted 
for P-emission in a RackBeta Scintillation Counter, after suspending in 10 mL of 
scintillation fluid. 
4. Results 
4.1. Escheriosomes fusion with model membrane systems: 
4.1.1. LUV-LUV fusion 
The potential of the escheriosomes to induce membrane-membrane fusion was 
assessed by monitoring the mixing of the lipids. The ftision efficiency w£is determined by 
measuring RET between NBD (photon donor, absorption at 470 nm, emission at 520 nm) 
and rhodamine (photon acceptor, absorption at 540 nm, emission at 585 nm). These 
probes were grafted on the LUV surface by including NBD-PE and Rh-PE in EPC/chol or 
E. coli lipids. The LUVs containing these two fluorophores (labeled vesicles) were diluted 
with increasing amounts of LUVs free of these fluorophores (unlabeled vesicles). The 
efficiency of RET was calculated by measuring the NBD fluorescence, as described in 
materials and methods. As the efficiency of RET between these fluorophores has been 
shown to depend on their concentration in the vesicle bilayer (Duzgunes et al., 1991), it 
was expected that any fiision between the labeled and unlabeled LUVs would lead to 
dilution of the probes and consequently in the reduction of the RET efficiency. Unlike the 
EPC/chol-LUVs, the RET in the case of the E. coli lipid LUVs decreased with an increase 
in the incubation time as well as with the ratio of the labeled to unlabeled LUVs. We 
observed that the efficiency decreasing to = 40% when the unlabeled/labeled ratio was 10 
(figure 3). Furthermore, the repetition of the same experiment with the liposomes that 
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Figure 3: Time courses. Time dependent effect on the efficiency of RET between 
NBD and rhodamine grafted on the LUVs surface upon mixing the labeled LUVs 
with increasing amounts of unlabeled LUVs. 
( • ) EPC/chol (labeled to unlabeled ratio = 2); ( • ) crude E. coli lipid (labeled to 
unlabeled ratio = 2); ( T ) reconstituted E. coli lipid (labeled to unlabeled ratio = 
2); ( O ) EPC/chol (labeled to unlabeled ratio =10); ( • ) crude E. coli lipid 
(labeled to unlabeled ratio =10); ( V ) reconstituted E. coli lipid (labeled to 
unlabeled ratio = 10). 
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were prepared with the reconstituted E. coli lipids [the lipids viz. 
phosphatidylethanolamine, phosphatidylglycerol and cardiolipin were isolated by 
preparative thin layer chromatography, and reconstituted in the liposomes in the same 
ratio (phosphatidylethanolamine/phosphatidylglycerol/cardiolipin, 82 : 14 : 4) as that of 
their abundance in the plasma membrane] produced more or less same fusion efficiency 
as determined by the RET assay (Figure 3). 
The membrane fusion potential of the bacterial lipids was further validated by 
observing the mixing of the aqueous contents during fusion by measuring quenching of 
the ANTS fluorescence by the water soluble quencher DPX. Incubation of the ANTS 
containing £. coli lipid LUVs with a 10-fold excess of DPX containing LUVs resulted in 
= 60% quenching of the ANTS fluorescence in 30 min (figure 4). However, no such 
quenching of the ANTS fluorescence was observed when ANTS-containing EPC/chol-
LUVs were incubated with a 10-fold excess of the DPX-containing EPC/chol-LUVs 
under identical conditions. 
4.1.2. LUV-erythrocyte membrane fusion 
Fusion of the escheriosomes with the erythrocyte membrane vesicles was studied 
by including a self-quenching concentration (5 mol %) of NBD-PE (Hoekstra et al., 1984) 
in the E. coli lipids or EPC/chol-LUVs bilayer. The NBD fluorescence dequenching was 
measured by fluorometry, subsequent to the fusion of these LUVs with the erythrocyte 
membrane vesicles. Unlike the EPC/chol -LUVs, E. coli lipid LUVs readily fuse with 
erythrocyte membrane vesicles, leading to =*= 60% dequenching of the NBD fluorescence 
in a time dependent manner (figure 5). 
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Figure 4: Time courses. Time dependent quenching of the ANTS fluorescence by 
mixing the ANTS-containing LUVs with DPX-containing LUVs in a ratio of 1:10 
( • ), EPC/chol; { o ) , E. coli lipids LUVs. Values are the mean of three 
independent experiments ± SD. 
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Figure 5: Time dependent interactions of the NBD-labeled K cgli lipid LUVs 
with the erythrocyte membrane vesicles. 
E. coli lipid (or EPC/chol) LUVs (750 nmol lipid/ mL) containing 5 mol % NBD-
PE in their bilayers were interacted with right side-out erythrocyte membrane 
vesicles (~ 10^  vesicles/mL) at 37 °C for varying periods of time. The NBD 
fluorescence was monitored up to 60 min incubation, using excitation and 
emission wavelengths of 470 nm and 520 nm respectively. The percentage of 
NBD dequenching was calculated as follows: 
Percentage dequenching = 100 x (i^ - FQ) I (Ft - FO) 
where F, FO and Ft are the fluorescence intensities at time 't', 0 min, and after 
adding Triton X-100 (1% fmal concentration), respectively. Time-dependent 
NBD-fluorescence dequenching upon interaction of NBD-labeled LUVs with 
erythrocyte membrane vesicles. ( • ) EPC/chol; (o) E. coli lipid LUVs. 
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4.2. Escheriosome fusion with tlie target cells: 
4.2.1. Escheriosome mediated transfer of membrane fluorescent marker (NBD-PE) 
to the macrophages 
The fusion potential of the E. coli lipids was also confirmed by observing transfer 
of fluorescent membrane marker (NBD-PE) from escheriosomes to the living cells. For 
this purpose, the E. co//lipid (or EPC/chol) DRVs containing 5 mol % of NBD-PE in the 
bilayers were allowed to interact with J774 A.l cells. The transfer of NBD fluorescence 
from DRVs to the membranes of macrophages was analyzed by fluorescence light 
microscopy. The results demonstrated that interaction with EPC/chol liposomes resulted 
in a punctuate type of fluorescence, while NBD fluorescence was mainly associated with 
membrane of the target cells (figure 6). Furthermore, our findings also suggest that the 
incubation of the cells with the escheriosomes in the presence of 100 |j,M chloroquine or 
at 0 °C did not appreciably affect the NBD-PE transfer. 
4.2.2. Intracellular distribution of ^^ I^-labelled lysozyme 
To analyze the interactions between escheriosomes and J774 A.l cells, these cells 
were incubated with '^^I-labelled lysozyme-encapsulated escheriosomes. The intracellular 
distribution of lysozyme was measured as described in materials and methods. 
IOC 
Approximately 18% of the total cell-associated I-labelled lysozyme was localized in 
the cytosolic portion of the macrophages that were incubated with the E. coli lipids-DRVs 
loaded with '^^I-labelled lysozyme (table 2). In contrast, only < 1% of the radioactivity 
could be detected in the cytoplasmic compartment of the cells that received treatment 
with the I-labelled lysozyme loaded EPC/chol-DRVs. These results suggest that the E. 
coli lipids DRVs possess a strong fiisogenic character that enables them to deliver the 
entrapped solutes into the cytosolic compartment of the antigen presenting cells. 
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Figure 6: Fluorescence light micrographs of the macrophages J774 A.1 after 
their interactions withDRVs labeled with NBD-PE. 
(A), (B) phase contrast and fluorescence light micrographs respectively, of the 
macrophages interacted for 60 min at 37 °C with NBD-labeled EPC/chol DRVs. 
(C), (D) Phase contrast and fluorescence light micrographs, respectively, of the 
macrophages interacted for 60 min at 37 °C with NBD-labeled E. coli lipids 
DRVs. Identical light micrographs were observed when the macrophages were 
interacted with NBD-labeled DRVs in the presence of 100 [xM chloroquine or at 
low temperature (4 °C). 
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Lipid 
Vesicles 
EPC/Chol 
E. Coli lipids 
Percent distribution of radioactivity 
Plasma 
membrane/ 
nucleus 
44 9 + 1 6 
42 4 ± 2 4 
Cytosol 
0 6 + 0 40 
182± 1 2 
Endosome/ 
ly so somes 
48 9 + 4 5 
35 2 ± 1 6 
Other 
organelles 
5 6 ± 1 2 
4 2 ± 0 9 
Table 2: Subcellular distribution of '^^I-lysozyme introduced in J774 A.l 
cells using K_ coli lipid DRVs as carriers. Values are mean of three different 
experiments ± SD 
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Figure 7: Escheriosomes mediated cytosolic delivery of 'ricin A \ 
Inhibition of cellular protein synthesis by 'ricin A' after J774 A.l cells were 
interacted with ricin A-loaded E. coli lipid DRVs. ( T ) Free ricin A; ( o ) ricin 
A-loaded in EPC/chol DRVs; ( • ) ricin A-loaded in E. coli lipids DRVs. Values 
are the mean of three independent experiments ± SD. 
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4.2.3. Inhibition of the macrophage protein synthesis by 'ricin A' 
The J774 A.l cells were incubated with DRVs loaded with the toxin 'ricin A'. 
Without the B chain, 'ricin A' is incapable of entering the cytosolic compartment of the 
target cells (Endo, et al. 1987). Any effect on the macrophage protein synthesis of the 
ricin A-loaded DRVs should confirm the membrane fijsion as one of the modes of the£. 
coli lipid DRVs-macrophage interactions. Our results indicate that, unlike its fi-ee or 
EPC/chol DRVs encapsulated form, 'ricin A' entrapped in the escheriosomes effectively 
inhibited protein synthesis in the macrophages in a dose-dependent manner (figure 7). 
5. Discussion 
Proteins contain the antigenic determinants for interaction with antibodies and T 
cell receptors (TCR), although unlike antibodies, the TCR do not directly interact with the 
native protein (Alving, 1991; Alving et ah, 1995). The protein first has to undergo 
extensive proteolytic degradation by the proteolytic enzymes of the host cell cytoplasm, 
leading to the generation of a set of relatively short peptide fragments. Nascent MHC 
class I molecules in the endoplasmic reticulum and class II molecules in the lysosomes 
are loaded with these peptides, and exported through the Golgi and the secretory 
pathways to the cell surface for recognition by either CD8* or CD4* T-cells respectively 
(Alving et al., 1995; Harding et ah, 1991). The soluble antigens have a tendency to 
undergo endocytosis after interaction with antigen presenting cells. The incorporation of 
such antigens in delivery vehicles, e.g. EPC/chol liposomes, usually results in the same 
fate except for an increase in overall antigen specific humoral immune response (Phillips 
and Emili, 1992; Therien et al, 1991; Just et al, 1992; Phillips et al, 1996). However, 
delivery of the same exogenous antigen in the cytosol of antigen presenting cells can 
induce a cytotoxic T lymphocyte in conjunction with heightened T-helper immune 
responses (Zhou et al, 1992; Nakanishi et al, 2000; Krishnan et al, 2000a). Ironically, 
the existing delivery systems, which have the potential of inducing simultaneous 
induction of humoral and CTL responses, are usually associated with toxicity, 
cumbersome preparation methodology and cost factors (Wijburg et al, 1998; Holzer et 
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al, 1996). Therefore, it is required to look for some alternate sources of fusogenic 
delivery systems that meet such requirements without causing toxicity. 
The fusogenic potential of escheriosomes was first demonstrated by RET assay 
experiments. The 'probe dilution' method is Icnown to be insensitive to vesicle 
aggregation (Duzgunes et ah, 1987). Furthermore, the fluorescent probes employed (viz. 
NBD and rhodamine) have been shown not to undergo any exchange between the 
phospholipid vesicles (Kok et al., 1991). We infer that the observed decrease in the RET 
efficiency is due to vesicle-vesicle fiision (figure 3). This was further confirmed by a 
content mixing assay where ANTS-encapsulating escheriosomes were shown to undergo 
membrane-membrane fusion with DPX (quencher) containing escheriosomes, which 
eventually led to the mixing of fluorescent probe and quencher resulting in decreased 
fluorescence (figure 4). Moreover, such a fiision phenomenon is not restricted to the 
model membrane only and natural membranes such as erythrocyte vesicles can also fiise 
with the escheriosomes that resulted in transfer of the fluorescent probe to the erythrocyte 
membrane (figure 5). Finally, the potential of escheriosomes to undergo fusion with 
living cells was demonstrated by epifluorescence microscopy. The results shown in figure 
6 demonstrated transfer of the fluorescent probes to the membrane of the target cells, 
while interaction with conventional EPC/chol liposomes follows an endocytosis mode and 
resulted in a punctuate type of fluorescence. 
To fiirther confirm that membrane-membrane fiision constitutes a major role in 
the escheriosome interaction with the J774 A.l cells, we studied the effect of 'ricin A' on 
macrophage protein synthesis. The J774 A.l cells were incubated with DRVs loaded with 
the toxin. 'Ricin A' is the A chain of the plant toxin 'ricin' which consists of two 
disulfide-linked polypeptides, A and B. While the B chain is responsible for the binding 
of toxin to virtually all types of the cells, the cytotoxic activity resides in the A chain, 
which after translocating into the cytosol, inhibits the cellular protein synthesis by an 
effect on elongation factor 2. Without the B chain, 'ricin A' is incapable of entering the 
cytosolic compartment of the cell (Reddy et al, 1991). The observed inhibition of the 
protein synthesis suggests that escheriosome entrapped 'ricin A' readily breaches the 
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membrane barrier to gain access to the cytoplasm of J 774 A.l cells even in the absence 
ofricinB (figure 7). 
To quantify the cytosolic delivery of macromolecules by the escheriosomes, we 
determined the distribution of radio-labeled lysozyme in different subcellular 
compartments. Although the major portion of the liposomes was directed to the 
endo/lysosomal compartments (table 2), a substantial amount (=« 18%) was able to reach 
the cytosol of the interacting cells. On the contrary, using other delivery systems (e.g. pH 
sensitive liposomes) the delivery efficiency lies between 1 and 10% (Stegmann et al., 
1989). 
Earlier it has been demonstrated that liposomes composed of yeast lipids may 
undergo membrane-membrane fusion with the plasma membrane of APCs (Owais and 
Gupta, 2000). Moreover, delivery of model antigens by yeast lipid liposomes successfully 
induced a CD8"^  CTL response in addition to strong CD4"^  T-helper response in 
immunized BALB/c mice (Owais et ah, 2001). Several experiments were performed to 
rule out the involvement of fusogenic proteins in the observed membrane-membrane 
fusion and such events are suggested to be solely attributed to the lipid components of the 
yeast. Interestmgly, during our work with bacterial lipids, we observed that various 
microbes such as Bacillus subtilis (phosphatidylethanolamine 30%; phosphatidyl glycerol 
12%) and Bacillus megaterium (phosphatidylethanolamine 32%; phosphatidyl glycerol 
68%) have anionic lipids as major constituents of their plasma membranes (Rattray, 1988; 
Jain, 1988). Our preliminary studies revealed a strong fusogenic potential of the lipids 
obtained from these bacteria and substantiate our hypothesis that the presence of these 
lipids fulfill certain physiological demands of lower organisms, in terms of a higher 
multiplication rate (Relini etal, 1994; Pluschke and Overath, 1981; Rattray, 1988; Owais 
and Gupta, 2000). 
Keeping into consideration the possible use of such lipids in vaccine development, 
the use ofE. coli lipids may offer several advantages over yeast lipids. These include less 
heterogeneity of phospholipids of the E. coli (phosphatidylethanolamine/phosphatidyl 
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glycerol/cardiolipin), which is likely to impart less toxicity risks as compared to the 
complex phospholipid mixture of the yeast membrane lipids. Furthermore, the generation 
time forE. coli (20 min) as compared to yeast (2 h) implies that the former grows much 
faster and requires less culture time when grown for the bulk isolation of the lipids, thus 
making the whole process more economical (Watson et ah, 1992). Moreover, the yield of 
the lipids from E. coli was found to be at least 4—5 times higher as compared to the yeast 
when isolated from the same biomass (wet weight) of the two organisms and favors the 
use ofE. coli as more economic source of fiisogenic lipids. Finally, we can conclude that 
the present study, besides providing better insight into the evolutionary frend m the 
disfribution of lipids in the plasma membrane of living cells, offers a promising approach 
for developing liposome-based antigen delivery systems that may have better 
repercussions in the vaccine development against various intracellular infections. 
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1. Introduction 
A book entitled Man's Mastery of Malaria reflected the general concept about 
malaria during that time period (Russell, 1955). Unfortunately, half century later malaria 
kills 2-3 million people a year (WHO, 1996). It is quite unfortunate to put on record the 
present statistics, which tells that one African child dies due to malaria every 30 seconds 
(WHO, 2000). 
The human malaria is caused by four species of the protozoan parasite 
Plasmodium that includes P. falciparum, P. vivax, P. ovale, and P. malariae. The life 
cycle and parasite-host interaction of each Plasmodium sp. determines the severity, 
pathogenesis, chronicity, and chronology of clinical form of the disease (Gilles and 
Warrell, 1993; Miller et al., 2002). Among various species, Plasmodium falciparum 
causes the greatest number of deaths, while P. vivax has the greatest geographical 
distribution (Sherman, 1998). Beside conditions that are conducive in mammaliein host, 
this parasite can thrive well in the environment that offers support to one of the 50 
species of Anopheles mosquitoes serving as the vector for its transmission (Sherman, 
1998). The situation gets worsened with the recent advent of resistance of Plasmodium sp. 
to chloroquine and of mosquitoes to DDT; spread of malaria enlarged its distribution in 
many parts of the world. Some of the major causes of this resurgence are the 
development of resistance to available drugs against Plasmodium (Greenwood and 
Mutabingwa, 2002), and insecticides (Hemingway et ah, 2002), increasing human 
migration and tourism (Muentener et al., 1999). 
1.1. Life cycle oiPlasmodium 
All strains of the malaria parasite have a complex life cycle that begins in the 
mammalian hosts when the female mosquito deposits 5 to 20 sporozoites subcutaneously 
during a blood meal (Rosenberg et al, 1990; Ponnudurai et al, 1991) (figure 8). The 
sporozoites enter the blood stream and within few minutes migrate to the liver and invade 
hepatocytes (Mota et al, 2001 &. 2002). Within this relatively immunoprotected 
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Figure 8: Malaria vaccines by life-cycle target. 
Target 1 (sporozoites) = RTS,S, ICC-1132, NYU CS, Lausanne CS; 
Target 2 (liver stage) = DNA and viral vectors (NMRC, Vical, and Oxford), 
* RTS,S, * Lausanne CS; 
Target 3 (blood stages) = MSPl, MSP2, RESA, MSP3, GLURP, FMPl, AMA-1; 
Target 4 (sexual stages) = Pvs25. 
The * in front of RTS,S and Lausanne CS indicates that these vaccines might also 
partly act against the liver stage as well as against sporozoites. (Moorthy et at., 
2004) 
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intracellular environment, each sporozoite develops over a period of 6 to 16 days into 
tens of thousands of schizonts. The schizonts rupture, releasmg 20,000 to 30,000 
merozoites per original sporozoite in to the hepatic venous circulation and from there 
they disseminate systemically. Plasmodium vivax and P. ovale can develop into 
hypnozoites, which might remain quiescent in the liver from months to years. It is only 
after the parasites erupt from the hepatocytes that symptoms of clinical disease are 
apparent. In the blood sfream, each merozoite that has escaped from phagocytic cells then 
invades, multiply, mature over 24 to 72 hours in the erythrocytes, and finally lyse them to 
invade fiirther new erythrocytes (the blood stage of malaria). The blood stage culminates 
in death of the host. Finally, some of the merozoites develop into sexual stage 
gametocytes, typically about 10 days after P. falciparum enters the blood stage (3 days 
for P. vivax). When these are taken up during blood meal by mosquitoes, they can 
sexually combine and develop into sporozoites (10 to 22 days) and this leads to the 
restarting of the cycle. 
1.2. Pathogenesis and Epidemiology 
The classical signs of symptoms of malaria in human beings include acute febrile 
episodes and rigors that occur every 48 to72 hours, which in fact coincide with the 
synchronized lysis of erythrocytes by newly matured merozoites. Systemic signs and 
symptoms associated with P. vivax include fever, malaise, headache, photophobia, 
muscle aches, anorexia, nausea, and vomiting (Markell et ah, 1992). Severe disease 
occurs most frequently with P. falciparum because of its ability to infect a greater 
percentage of erythrocytes and to cytoadhere to capillary walls (Markell et al, 1992; 
Miller et al, 2002). Clinical sequelae (such as acute renal failure, anemia, hypoglycemia, 
cerebral malaria, and pulmonary edema) occur most commonly in populations that are 
relatively immuno-naive to the parasite, such as children and travelers from non-endemic 
area (Chen et ah, 2000). Pregnant women are at special risk for severe disease and 
sequelae, including a unique mechanism of pathogenesis (Reeder, 1999). 
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Quantification of the malaria parasite burden in affected populations is imprecise, 
impacted mainly by their access to diagnostic and therapeutic health centers, species 
prevalence, case definition, and low specificity of diagnosis (Breman, 2001; Murphy and 
Breman, 2001). It is thought that there are 300 to 500 million clinical cases per year 
globally, about 25% of which are caused by P. vivax. Estimated annual malaria attributed 
deaths vary jfrom 1.4 to 2.7 million (Breman, 2001; Snow et ah, 1999) with the majority 
of deaths occurring in children in the Afiican continent (Snow et al., 1999). This 
translates into 39 million disability-adjusted life years lost annually (WHO, 1999), which 
in turn tells about the impact of the disease on economic and social disruption in 
developing countries (Gallup and Sachs, 2001). 
The number of malaria cases diagnosed within the United States has been stable 
at approximately 1000 to 1500 per year over the past decade, with the vast majority of 
cases are reported among travelers and military personnel overseas. However, the United 
States has very small number of congenital, blood transfusion, and locally acquired cases 
(Holtz et al., 2001; Sunstrum et al., 2001). On the other hand, European countries has a 
much higher rate of malaria, with 37,000 autochthonous and 13,000 imported cases as per 
survey made in 1999 (Sabatinelli et al., 2001). 
1.3. Vaccinology 
Multiple lines of evidence suggest that a malaria vaccine for humans is feasible. 
Immunization of humans with irradiated (and thus attenuated) sporozoites confers sterile 
protection in roughly 90% of naive volunteers when they are subsequently exposed to 
malaria (Clyde, 1990; Egan, 1993; Rieckmann et al., 1979). Because this model requires 
each volunteer to be bitten by hundreds of mosquitoes over a period of several months, it 
is not a practical vaccination strategy but is useful in probing immune responses 
(Hoffrnan et al., 2002). Naturally acquired clinical immunity occurs during the first two 
decades of life in people living in malaria-endemic areas (Trape et ah, 1994; Baird, 1991). 
In general, this immunity is imperfect, can wane rapidly, appears to be linked to intensity 
of exposure, and prunarily impacts the severity of the clinical disease (Day and Marsh, 
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1991; Baird, 1998; Hogh, 1996; Smith et al, 2001). Additionally protection can be 
mimicked by the passive transfer of hyperimmune immunoglobulin into human 
volunteers (Sabchareon et al., 1991). 
The immunologic correlate for clinical protection has yet to be identified. 
Through its complex life cycle, the malaria parasite exists in various immunologic 
"compartments." It is advisable to explore nature of immune responses that might impact 
the parasite in the life cycle stage specific manner. Furthermore, it is possible to 
extrapolate from other malaria intervention studies how exactly the various stage specific 
vaccines might work. Ultimately, it might be necessary to combine antigen from various 
stages of the plasmodial life cycle into a single vaccine. Presently, there are three 
intermediate goals of vaccine research (Beverley, 2002): identification of protective 
antigens for stage specific immunity; successftil combination of candidate immunogens; 
and finally, the induction of sfrong, strain-franscending, durable immune responses. 
Whereas, the main strategy for development of a malaria vaccine falls under following 
categories: 
I. Blocking the sporozoite from invading or developing within hepatocytes; 
II. Blocking merozoite invasion of red cells and inhibiting development of 
schizonts; 
III. Blocking the adverse pathology-inducing effects of cytokines and parasite 
sequesfration; and 
IV. Developing an 'altruistic' vaccine that would block host-mosquito 
transmission by immunizing against the sexual stages or gametes. 
1.3.1. Pre-Erythrocytic vaccines 
Vaccine strategies targeting the sporozoites aim to generate a humoral immune 
response to neutralize the sporozoites and prevent it from invading the hepatocytes. Once 
the sporozoite has entered the relative immunoprotected intracellular environment of a 
hepatocyte, a successfiil vaccine strategy would rely upon elimination of infected 
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hepatocytes with the help of CTL (Doolan and Hoffinan, 2000). Experiments in ortholog 
model systems and irradiated sporozoite challenge studies have implicated CD4"^ , CD8^, 
natural killer T-cell, and y5 T-cells in the inhibition of intrahepatic parasites (Gonzalez-
Aseguinolaza et al., 2000; Nardin and Nussenzweig, 1993; Tsuji et al, 1990 & 1994; 
Good and Doolan, 1999; Doolan and Hoffman, 1997; Nardin et al, 1999). The leading 
candidate vaccine of this category is RTS,S - a recombinant protein vaccine (Stoute et al, 
1997). 
The passive transfer of antibodies specific to the sporozoite was found to be 
protective in the murine ortholog model systems (Marussig et al, 1997). Moreover, a 
dominant feature of the immune response induced by infecting humans with irradiated 
sporozoites is an antibody response to the circumsporozoite protein (CSP), the major 
component of the sporozoite surface coat of Plasmodium sp (Herrington et al, 1991; 
Egan et al, 1993). The role of antibodies in mediating protection was elegantly 
demonstrated with the use of MAbs that neutralized the infectivity of sporozoites in a 
rodent model (Potocnjak et al, 1980). Initial clinical studies used either a synthetic 
peptide or recombinant protein containing multiple copies of the immunodominant repeat 
sequences found in the CSP (Herrington et al, 1987; Ballou et al, 1987). For example, 
the peptide (NAN?)"' was conjugated to tetanus toxoid, whereas the recombinant protein 
containing 32 CSP repeats fiised to an out-of-frame 32 amino acid sequence from the 
gene encoding bacterial tetracycline resistance. A small number of subjects immunized 
with each of these CSP vaccines, formulated with alum, were challenged with infected 
mosquitoes. One of the three high titer responders to the peptide vaccine was protected 
(Herrington et al, 1987), whereas only one of six individuals challenged after receiving 
the recombinant CSP vaccine was protected (Ballou et al, 1987). Ironically, the 
following studies including numerous additional trials were carried out over a period of 
ten years with disappointing results (Rogers and Hoffman, 1999). 
More recently, results with a recombinant hepatitis B surface antigen vaccine 
incorporating repeat and non-repeat CSP sequences have been much more encouraging. 
When the hybrid hepatitis B particles were formulated in an oil-in-water emulsion 
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containing monophosphoryl lipid A and QS21, six of the seven immunized volunteers 
were protected against subsequent malaria challenge (Stoute et al, 1997). This vaccine 
was designated as RTS,S and assessed with thrombospondin-related anonymous protein 
(TRAP) which failed to impart protective immunity against malaria (Stoute et a/., 1997). 
In a randomized controlled field trial of three-dose RTS,S in Gambian adults, vaccine 
efficacy was 34% (p=0.014) during the 15-week surveillance period, but with 71% 
efficacy in the first 9-weeks and 0% in the next 6 weeks (Bojang et al., 2001). Moreover, 
the protection was not strain specific (Alloueche et al., 2003), although the duration of 
the efficacy was short, RTS,S is the first pre-erythrocytic vaccine to show clear 
protection against natural P. falciparum infection. Another vaccine candidate ICC-1132 
is a hepatitis B core particle, includes a region of CS for high antibody production. High 
titers of biologically active CS antibodies have been noted in preclinical studies (Birkett 
et al., 2002). Although, latest trials with DNA vaccination proved to be efficient priming 
vaccines but failed to boost efficiently (Schneider et al., 1999), still intense efforts are 
being made to develop effective DNA based vaccines, each encoding a pre-erythrocytic 
antigen, have undergone phase I studies (McConkey et al., 2003). 
Other CS-based candidate vaccines that have reached phase-I studies include a 
multiple antigen peptide, a type of synthetic delivery system, which induced strong 
antibody responses; a polyoxime construct, containing a universal T-cell epitope; and a 
long synthetic peptide in an oil-based adjuvant, which induced detectable antibodies and 
CD4" and CD8^ T-cell responses with a good safety profile (Nardin et al, 2000 & 2001; 
Lopez e/a/., 2001). 
1.3.2. Asexual Blood-Stage Vaccines 
There are two possible classes of blood-stage vaccine: anti-invasion and anti-
complication. Merozoites enter the blood stream after erupting from the hepatocyte. 
Within seconds they invade red blood cells that do not express MHC molecules. Hence, a 
vaccine that could prevent invasion would prevent malaria disease. For this reason, the 
vaccine strategy has classically been considered antibody dependent, either by 
60 
inactivating the merozoites or by targeting malarial antigens expressed on the red blood 
cell surface to anibody dependent cellular inhibition (or possibly complement lysis) 
(Bouharoun-Tayoun, 1995; Long, 1993; Holder et al., 1999). Recently, ortholog malaria 
models have implicated CD4"^  T-cells, nitric oxide, and yS T-cells in helping control 
blood stage parasites (Good, 2001; Bouharoun-Tayoun, 1995; Long, 1993; Holder et al., 
1999), and there is increasing evidence CMI can play a role in human protection (Plombo 
et ah, 2002). Vaccines developed against this stage would serve as disease-reduction 
vaccines, mimicking naturally acquired immunity by suppressing the exponential 
multiplication of merozoites (Tsuji et al., 2001; Richie and Saul, 2002). 
The two leading asexual blood stage vaccine candidates against Plasmodium are 
merozoite surface protein 1 (MSP-1) and apical membrane antigen-1 (AMA-1). Both of 
these antigens have been identified in all Plasmodium spp examined and the availability 
of their homologues in rodent and simian parasites has facilitated the assessment of MSP-
1 and AMA-1 vaccines in several animal models. MSP-1 is the most well characterized 
antigen involved in invasion, and is the basis of several candidate vaccines. Most interest 
in MSP-1 is currently focused on fragments that include the two C-terminal epidermal 
growth factor (EGF)-like domains. Inhibitory MAbs react with a 19 kDa fragment (MSP-
I19) but this fragment is poorly immunogenic (Chappel and Holder, 1993). hnmunity 
induced by immunization with C-terminal fragments of MSP-1 appears to be mediated by 
antibodies reacting with conformational epitopes in the EGF-like domains. The effective 
antibodies to MSP-I19 block invasion of merozoites, while the other antibodies reacting 
with the EGF-like domains are either neutral or block the action of the inhibitory 
antibodies (Blackman et al., 1994). In a small efficacy study in Papua New Guinea, a 
blood stage vaccine incorporating the antigen MSP-2 and two other blood stage antigens 
reduced parasite density in vaccine recipients (Genton et ah, 2002). Participants were 
protected most from infection with the vaccine strain of malaria, suggesting that for 
polymorphic antigen such as MSP-2, a vaccine including just one allelic form of the 
antigen is not likely to give sufficient protection. Immunization with recombinant forms 
of AMA-1 has protected monkeys and mice against challenge with P. fragile and P. 
chabaudi, respectively (Collins et ah, 1994; Crewther et al., 1996). 
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A recombinant viral vaccine, NYVAC Pf-7 encoding seven antigens from 
different stages of malaria life cycle (Ockenhouse et al., 1998) has shown to suppress 
parasitemia upon challenge with sporozoites. The immune response generated by this 
vaccine included some humoral as well as CTL. Two more blood-stage candidates, 
glutamate rich protein (GLURP) and MSP-3, have been clinically assessed (Oeuvray et al. 
2000 & 1994). Main emphasis of all such protein candidates is the identification of a safe, 
immunogenic adjuvant, since the traditional adjuvant alum seems to be insufficiently 
immunogenic for many malaria proteins. In addition, this adjuvant induces a Th-2 
response rather than a desirable Th-1 response. 
The erythrocyte membrane protein-1 antigen (PfEMP-1), the ligand responsible 
for adherence of malaria parasite to vascular endothelial cells in the brain, kidneys and 
placenta, is being used in experimental laboratory vaccine trials. However, due to high 
degree of variability, rapid antigen variation and high copy number within each parasite, 
use of this antigen in vaccines becomes complicated as researchers believe in using a 
conserved part of the antigen to be more promising. The P. falciparum glycosyl 
phosphatidylinositol (GPI) molecule that is an inflammatory mediator released during 
schizont rupture has shovrai its efficacy as vaccine candidate in experimental animals 
(Schofield et ah, 2002; Molano et al., 2000). Two more GPI-anchored membrane 
proteins of trophozoite and merozoites stages of P. yoelii offered protection against lethal 
malaria infection in BALB/c mice (Bums et al., 2000). On sequencing these antigens 
were found to contain two epidermal growth factor (EGF)-like domains. 
1.3.3. Transmission-Blocking vaccines 
Transmission-blocking vaccines rely on the mosquito imbibing both anibody and 
complement along with the parasite during a blood meal. Within the mosquito, the 
antigens become exposed to antibodies during the parasite's maturation, thus neutralizing 
the sexual stages (Kaslow, 1993; Lobo et al., 1999; Hisaede et al., 2000). This type of 
vaccine would not prevent illness or infection in the vaccinated individual, but would 
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prevent the further spread of malaria by mosquitoes feeding from the vaccinated host 
(Kaslow, 1997; Stowers and Carter, 2001). Such a vaccine could be usefiil in areas of low 
endemicity to halt transmission or as an important component of a multi-antigen vaccine. 
Only few reports are available addressing the exciting developments with DNA 
vaccines (Hedstrom et ah, 1998), multiple antigenic peptides (Moreno et al, 1999), or 
artificial proteins containing multiple epitopes and / or domains (Shi et ah, 1999). There 
has been a remarkable increase over a past decade in our understanding and knowledge of 
the malaria parasite and the disease that it causes. Never before has one been in the 
position to appreciate what a sophisticated and complex organism we are attempting to 
defeat through vaccine development. Nevertheless, we believe that pre-erythrocytic and 
asexual blood stage vaccines are now a reality and priority of malaria vaccine 
development is to field-test the large number of vaccine candidates that have been 
identified with various adjuvant combinations. 
1.3.4. Subunit vaccination 
The production of live attenuated or killed inactivated vaccines is not practical for 
many diseases. In subunit vaccination, part or complete antigen are identified from a 
pathogen's proteomic complement, which can induce protective immunity to the whole 
pathogen on vaccination. However, for successful elimination of the parasite, induced 
antibodies must have the correct avidity, specificity, biological activity, and be produced 
at a high enough titer to block the infection. Nevertheless, varying immunogenicity of the 
proteins may be the key factor for successful vaccination. Increased understanding of 
antigen processing, adjuvants and their effects on innate immunity, genetic engineering 
techniques, and novel antigen delivery systems have facilitated the increased 
immunogenicity of proteins. Unfortunately, recombinant protein subunit vaccines are 
generally poor at induction of effector T-cell responses, such as CD8"^  cytotoxic T 
lymphocytes, that are necessary for elimination of intracellular pathogens such as liver-
stage malaria parasites. 
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Presently, several laboratories are emphasizing on DNA based subunit vaccines 
(Ulmer et al., 1993; Li et ai, 1993). The strategies in such kind of vaccination may be 
either to use DNA sequences from malaria parasites that have been inserted into plasmid 
DNA molecules (DNA vaccines) or using various recombinant attenuated DNA viruses 
(recombinant viral vaccines) to generate candidate vaccines (Schneider et al, 1998). One 
of the benefits associated with DNA vaccines may be in the induction of memory T-cell 
population (Gurunathan et al, 2000). Recombinant viral vaccines actively infect cells and 
express the recombinant malaria proteins before aborting infection (Miyahira et al., 1998). 
DNA or recombinant viral subunit vaccines can induce high levels of effector T-cell 
immune responses, but poor antibody responses limits use of such vaccines (Gurunathan 
e/a/., 2000; Paoletti, 1996). 
1.3.5. Liposomal malaria vaccines 
The identification of protective antigens and adjuvants is a challenge for vaccine 
development in the fight against the world's most common infectious killers, including 
malaria. Nevertheless, merely identification of antigen does not help in solving some key 
problems in malaria vaccine development while induction of a strong and durable 
immune response is prerequisite for successful vaccination against this deadly parasite. 
Adjuvants impart variety in humoral as well as cell mediate immune responses or may 
even stimulate a differential IgG isotype expression (Richards, 1998; Kenney et al, 
1989). Hence, the selection of adjuvants or antigen delivery systems is crucial for 
achieving high efficiency of malaria subunit vaccines. In this regard, new vaccine 
delivery methods and adjuvants can be brought into practice that may eventually lead to 
the induction of desirable humoral as well as cellular immunogenicity. 
By using experimental animal models, number of workers have tried to achieve 
various levels of protection with crude preparations of blood-stage antigens with 
adjuvants against Plasmodium sp. (Bums et al., 1997; McColm et al., 1982; Playfair and 
De Souza, 1987; Playfair et al., 1977; ten Hagen et al., 1993; Patterson et al., 1999; 
Hunter et al., 1995; Desowitz, 1975; Murphy and Lefford, 1978; Kumar et al., 1990; 
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Reese et al, 1978; Siddiqui, 1977 & 1978; Targett and Fulton, 1965; Mitchell et ah, 1979; 
Brown et al, 1970). Adjuvants used in these studies included Freund's adjuvant, saponin, 
alhydrogel, IFN-y, nonionic block polymers, detoxified LPS, Quil A as well as bacteria, 
-including Bordetella pertusis, Comybacterium parvum and Salmonella typhimurium all 
of which produced mixed results. Apart fi-om these adjuvants, protective immunity 
against experimental P. falciparum challenge was achieved after immunization of 
humans with Al(OH)3-adsorbed recombinant proteins, or a peptide-tetanus toxoid 
conjugate containing repeat epitopes (Ballou et ah, 1987). Unfortunately, these 
combinations were poorly immunogenic in some cases (Ballou et al., 1987; Herrington et 
ah, 1987; Etlinger et ah, 1988). Moreover, a large population of these immunologically 
active microbial molecules including bacterial LPS is associated with unfavorable 
complications like fever or end-organ damage in septic patient (Egil et. al, 2003). 
Hence, the selection of adjuvants or antigen delivery systems without any side 
effect is crucial for achieving high efficiency of subunit vaccines. In an effort to improve 
immunogenicity of repeat based malaria antigen, variety of Al(OH)3-adsorbed candidate 
liposomal vaccines containing lipid A or monophosphoryl lipid A (MPLA) were 
evaluated in animal models (Alving et ah, 1986; Richards, 1988 & 1989; Alving and 
Richards, 1990). Moreover, recombinant antigen (R32NSl8i) was found to be more 
effective in humans in its liposomal form rather than with A1(0H)3 or other adjuvants 
(Fries et al, 1992). Purified parasite gp 195 entrapped in liposome B30-MDP with LA-
15-PH (synthetic equivalent ofE. coli derived MPLA), evoked higher humoral response 
than FCA in mice (Hui et al, 1991). In a study on MSP-1 derived 83.1 portion spf66 on 
its encapsulation into influenza virosomes elicited higher immune response than 
commercial whole virus influenza vaccine (Poltl-Frank et al, 1999). Interestingly, 
efflcacy of liposome as antigen delivery vehicle against malaria was also found effective 
against other stages of P. falciparum as CSP antigen entrapped in MPLA/liposomes 
revealed the higher efficacy of liposomal vaccine as compared to previously used 
CSP/A1(0H)3 formulation (Alving et al, 1986; Richards et al, 1988). 
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The use of adjuvant can critically influence the quality of immune responses. For 
example, it is well known that the Ig subclasses can be influenced by the use of adjuvants. 
Studies on rodent and humans malarias have suggested that immunity may be associated 
with differential expression of malaria specific Ig classes (White et al., 1991; Bouharoun-
Tayoun and Druilhe, 1992). Enhancement of certain Ig isotypes (e.g. IgG2a/IgG2b) can 
be achieved by adjuvant formulations such as Thr-MDP and or nonionic, pluronic 
polymer, liposomes, lipid A derivatives, and their use may favor induction of a protective 
antibody population. Nevertheless, CTL response has been demonstrated to play a key 
role in immunity to the liver stages of malaria (Schofield, 1989) and the use of liposomes 
may facilitate antigen specific CTLs (Alving, 1995). 
Taking into consideration the need of desired immune response against malaria, 
choice of an adjuvant formulation is likely to have a major impact on immunologic 
recognition of parasite and help in designing of subunit vaccines. Since most basic 
studies on immune specificity and mechanisms of immunologic recognition require in 
vivo priming of animal hosts by delivery of the antigen together with an adjuvant, the 
nature and characteristics of immune responses observed and the interpretation of the 
results may largely be restricted within the context of the adjuvant used. Along the same 
line, in the design of subunit vaccines, it may not be useful to exhaustively define 
immune responses to vaccine antigen using FCA adjuvant because it is too toxic to be 
used clinically. Therefore it will be necessary to characterize the immunogenicity of 
antigens using clinically acceptable adjuvant such as liposomes. 
2. Scope and plan of the present study 
The alarming development of multiple drug resistance in Plasmodium and the 
increased resistance of its vector, the Anopheles mosquito, to DDT underscore the 
importance of developing new chemotherapeutic means to hinder the spread of malaria. 
This has led to opt for prophylactic measures as complementary tools for controlling this 
dreadful disease, which in turn requires in-depth understanding of basic immunological 
complexities involved in the resolution of the disease. In spite of numerous efforts made . 
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for the development of the effective vaccines that provided crucial knowledge about 
immunological mechanisms involved as well as their respective target antigens, still no 
effective malaria vaccine is available. 
One approach of developing vaccines seems to be easy and straight forward that 
involves identification of protective antigens of malaria parasite and finally to develop 
suitable means for immunization. However, this could be true for some bacterial or viral 
infections, where development of pathogen specific antibodies successfiilly eliminate the 
pathogens from the systemic circulation of the host (Plotkin, 2001; Chanock et ah, 1993; 
Griffin et ai, 1992). In contrast, number of factors can be considered responsible for the 
low level of immune responsiveness to Plasmodium infection. For example, the 
maturational changes from sporozoite to gametocytes via intermediate merozoite stage 
allow the organism to keep changing its surface phenotype, resulting in less interaction 
with immune components of the host. On the other hand, intracellular phases of the 
parasite in liver cells and erythrocytes avoid direct interaction with pathogen specific 
antibodies, propagated by the immune system of the host to eliminate pathogens from 
systemic circulation. The asexual blood stage, which is responsible for the clinical 
symptoms of malaria as the parasite invades and destroys the host's erythrocytes and 
grows at an exponential rate, is also susceptible to immune intervention (Cohen, 1994; 
Langhome et al., 2002). Hence, much of the efforts from earlier studies included 
identification of potent immunogens from blood stages of malaria (as discussed above). 
However, many reports are available which revealed that selection/development of 
appropriate adjuvants and delivery system is as crucial to improve the efficacy of malaria 
vaccines as the identification of new protective antigens are and it has been shown in the 
earlier studies that protection against P. yoelii malaria can also be induced by 
immunization with crude preparations of blood stage antigens in various adjuvants 
(Bums et al, 1997; Patterson et al, 1999; Hunter et al, 1995; ten Hagen et al, 1993). 
Moreover, it is a well known fact that beside intrinsic properties of the antigen, certain 
factors such as access of the immune cells to the antigen, cytokine milieu, Thl/Th2 
polarization etc. may play crucial role in development of desirable vaccine. 
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Immunization with crude particulate fraction of a blood-stage antigen preparation 
protects against lethal as well as non-lethal P. yoelii infection (Bums et al., 1997). Both 
Thl and Th2-type cytokines were produced in protected mice, with a bias toward a Th2 
phenotype evident. In addition, the protection was shown to be B-cell dependent and 
associated with the production of parasite specific IgGl and IgG2a antibodies. This 
particulate antigen fraction, designated pAg represented 25-30% of the total P. yoelii 
blood stage preparations. Of particular interest, protective immunization induced 
antibodies that recognized a limited subset of six to eight P. yoelii antigens. 
Although protection against intracellular pathogens {e.g. Afycobacterium, 
Leishmania, etc.) in vivo is considered to be dependent on cellular immune responses, 
which require active involvement of CD4"^  as well as CD8"^  T-cells for successful 
elimination of murine and human infections (Agrewala and Wilkinson, 1998; Flynn et al., 
1993). Furthermore, immunity to the liver stages of malaria has also been demonstrated 
to be imparted by CDB"^  T-cell dependent (Nickell et ah, 1993). Surprisingly, immunity 
to blood stages of the malaria parasite is even more complex that requires active 
involvement of CD4^ T-cells, B-cells, and IFN-y (Bums et al., 1997; Patterson et al., 
1999; Zhong et al., 2003), which have been claimed to evoke desired cell mediated as 
well as humoral immune responses for successful elimination of parasites from the 
systemic circulation (Langhome et al., 1990; Hunter et ah, 1995; Melancon-Kaplan et al., 
1992). Moreover, earlier investigations suggested that protection against blood stage 
malaria requires both Th-2 and Th-1 cellular responses, especially the latter in 
conjunction with strong humoral immunity (Langhome et ah, 2002; Blomberg et al., 
1999; Mohan and Stevenson, 1998; Suss and Pink, 1992), where IgG2a type of antibodies 
are efficient in controlling infections (Wendy et al., 1991). 
In the present study, we have tried to establish the practical utility of 
escheriosome based vaccine against experimental blood stage malaria in a murine model 
of a multidmg resistant (MDR) Plasmodium yoelii nigeriensis. The data of the present 
study revealed that escheriosome encapsulated soluble blood stage antigens of P. yoelii 
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can invoke strong malaria specific cell mediated immune responses as well as protective 
antibodies in BALB/c mice. 
3. Materials and Methods 
3.1. Animals and parasite 
Inbred female BALB/c mice (8-10 weeks old), of 20+2 gm. weight, were obtained 
from the institute's Animal House Facility. Plasmodium yoelii nigeriensis MDR (a lethal 
strain) was obtained from division of Parasitology, Central Drug Research Institute, 
Lucknow. The parasite was fully resistant to chloroquine 128 mg/kg x 4 dose; quinine 
600 mg/kg X 4 days and mefloquine 256 mg/kg x 4 doses and was maintained in vivo in 
mice by routine passage (Dutta and Pandey, 1986). The techniques used for bleeding, 
injection as well as sacrifice of animals were strictly performed following mandates 
approved by the Animal Ethics Committee (Committee for the purpose of control and 
supervision of Experiments on Animals, Govt, of India). 
3.2. Chemicals and Reagents 
Egg phosphatidylcholine (EPC) was isolated and purified following a standard 
procedure (Singleton et ah, 1965). Cholesterol (Choi) was purchased from Centron 
Research Laboratory, Mumbai, India. [^H]-thymidine was bought from Bhabha Atomic 
Research Center, Mumbai, India. Monoclonal anti-mouse CD4, CD8a, CD80 and CD86 
FITC conjugates and their isotype confrol (purified Rat IgG2a isotype) were from Sigma 
Immuno Chemicals, St. Louis, USA. 
3.3. Preparation of liposome encapsulated P. yoelii antigens 
Crude soluble antigens from P. yoelii were prepared by the method of Amante 
and Good with minor modifications (Amante and Good, 1997). Briefly, blood from 
Plasmodium yoelii nigeriensis (MDR) infected mice was collected when the average 
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parasitaemia reached 40-45 %. Mouse leukocytes were removed by passage of blood 
over Cellulose CF-11 columns. RBCs were collected and lysed with 0.01% saponin (For 
30 min at 4°C). hitact parasites were obtained by centrifiigation at 10,000x g and further 
washed with PBS to remove soluble RBC proteins. The parasites were suspended in IM 
PBS and sonicated for 30 min (1 min pulse with 30 seconds rest) with a probe type 
sonicator. The sonicated mixture was centrifuged at 10,000 x g (for 15 min at 4°C). The 
supernatant containing soluble fraction of antigens (sAg) was collected after filtration 
through 0.2 ]xin Whatman filter devices and estimated for its protein content. For 
liposome preparation, lipids were isolated from E. coli cells (log phase) and the 
liposomes of both types (escheriosomes and EPC/chol liposomes) were prepared 
essentially by following the published procedure and the amount of protein entrapped in 
the liposomes was estimated as modified in our lab (Owais and Gupta, 2000). 
3.4. Immunization and P. yoelii infection 
For immunological as well as protection studies BALB/c mice were immunized 
subcutaneously with various preparations [IFA-sAg (sAg emulsified with equal volume 
of IF A) or sAg entrapped in either type of liposomes] of sAg (100 ng/animal) or sham 
escheriosomes (empty escheriosomes without sAg) at day 0, 21 and 28. Control group 
mice received same volume of either PBS only or sham escheriosomes. For protection 
studies, BALB/c mice (n=10) were challenged on day 35 post primary immunization, 
intraperitoneally with 10^  parasitized RBCs of i*. yoelii nigeriensis (MDR) strain. Control 
groups of mice received PBS only. 
3.5. FACS analysis 
The expression of CD4'*' as well as CD8"^  T-cells was compared among single 
spleen cell suspensions derived from spleens of various experimental groups by direct 
immunofluorescence staining. As per manufacturer's instruction 1 x 10^  spleen cells of 
mouse (n=5 from each group) were stained with fluorescein isothiocyanate (FITC)-
conjugated monoclonal antibodies specific for mouse CD4 and CDSa. The cells were 
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incubated for 30 min at 4 °C, washed three times with dilution buffer (0.0IM phosphate 
buffer saline, pH 7.4 containing 1% bovine serum albumin, 0.1% sodium azide) and 
resuspended in 500 \i\ of 2% paraformaldehyde. However, for determining the percent 
expression of costimulatory molecules, blocked peritoneal macrophages (1 x 10^  
thioglycollate elicited peritoneal macrophages harvested from BALB/c mice) were 
incubated in RPMI media with either free sAg or with its encapsulated forms in 
escheriosomes and EPC/chol liposomes (sAg 10 [ig/mL in each formulation) for 48 h. 
After incubation, the cells were stained with either anti-CD80 or anti-CD86 FITC 
conjugated MAbs. The percentage of positive cells was measured with a fluorescence-
activated cell sorter (Becton Dickinson) and data was analyzed by CellQuest Software 
(Becton Dickinson). 
3.6. Spleenocytes proliferation assay 
One week after the final immunization dose the spleens were removed aseptically 
from animals of each group. The spleen cells were squeezed out in lOmL of RPMI 1640 
(Gibco) supplemented with 5% heat inactivated FCS (Sigma), 25mM HEPES (Gibco), 
0.12% gentamicin (Sigma). Cell suspension was passed through 75|4m cell stainer 
(Falcon, USA) to obtain a single cell suspension and centrifiiged at 500x g for 10 min. 
RBCs were lysed with 0.83% chilled NH4CI (1:3), and the cells were washed twice with 
fresh medium and quantified in a Neubauer haemocytometer (Germany). The viability of 
the cells was determined by tryptan blue exclusion and was found > 90%. Cell 
concentration was adjusted to 5x10^ cells/mL in complete medium and aliquots of O.lmL 
were plated in friplicate in 96-wells flat bottom plates (Nunc, Roskilde, Denmark), to 
which were added 100 [il of complete media alone (for confrol unstimulated cultures) or 
with matching formulations (viz. escheriosome or EPC/chol liposome entrapped and free) 
of blood stage sAg (final concentration 10 jig/mL). Cultures were incubated for 3 days 
(37^C, 5% CO2) and after that DNA synthesis was monitored by pulsing lp,Ci of tritiated 
thymidine (^H-Tdr, specific activity 18Ci/m mole, BARC, India) per well to the cultures 
as a terminal 18 hours pulse. The radioactive incorporation was measured by standard 
liquid scintillation counting. The stimulation index (SI) was calculated as mean cpm 
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values of stimulated culture/ mean cpm values of unstimulated culture. An SI > 2 was 
considered significant. 
3.7. Cytokine assays 
Cultures of spleen cells were performed, as described above for spleenocytes 
proliferation assay from BALB/c mice of various experimental groups. The culture 
supematants from the wells were collected after 48 h for IL-4 and IFN-y estimation. 
Cytokine levels were measured by sandwich ELISA (Mosmarm and Fong, 1989). The 
levels of cytokines were calculated by standard curves that were plotted using 
recombinant cytokines Pharmingen) and are expressed as picograms per milliliter. 
3.8. Determination of antigen specific IgG isotypes by ELISA 
Mice from all experimental as well as control groups were bled on day 35 post 
primary immunization to observe the presence of antibody isotypes. Briefly, ninety-six 
well microtitre plates were incubated overnight with crude P. yoelii antigen (25 |i.g/mL) 
diluted in carbonate-bicarbonate buffer (0.05 M, pH 9.6) at 4 °C. After usual washing 
with PBS-T (PBS with 0.05% Tween-20), plates were blocked with 5% skimmed milk 
powder (in PBS) before incubating with different dilutions of all test as well as control 
sera obtained at day 7 post final booster (at 37 °C for 2h). After washing of the plates 
with PBS-T, these were fiirther incubated for overnight with monoclonal goat anti-mouse 
IgGl, IgG2a and IgG2b antibodies (Sigma). After the usual washing steps, HRP 
conjugated rabbit anti-goat IgG (Sigma) were added to each well and the plate was 
incubated at 37 °C for 2h. The plate was washed again with PBS-T before developing 
them with the OPD substrate (o-phenylene diamine dihydrochloride; Sigma). The 
absorbance was read at 492 nm with a microtitre plate reader (Eurogenetics, Torino, 
Italy). 
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3.9. Immunoblot assay 
Whole blood stage antigen was separated on a 4-17% linear gradient sodium 
dodecyl sulfate-polyacrylamide gel (SDS-PAGE) as described earlier (Laemmli, 1970) 
and electrophoretically blotted onto nitrocellulose membrane The transferred protein 
bearing strips were incubated with 1:200 dilutions of mouse sera in 1% skimmed milk-
PBS at 37°C for 90 min, washed three times with PBS-T (IM PBS, 0.05% Tween-20), 
and incubated with a 1:1,000 dilution of HRP-conjugated goat anti-mouse 
immunoglobulin (Sigma Immunochemicals, USA) for 90 min at 37^C. The strips were 
washed thrice, incubated with substrate [0.3% DAB (Sigma) in PBS with 0.4% H2O2] till 
the development of color, and finally washed thrice with triple distilled water. 
3.10. Antibody titration by indirect immunofluorescence (HF) 
Parasitized blood was collected from mice infected with P. yoelii (MDR) when 
parasitemias averaged 15 to 20%. Erythrocytes were pelleted by centrifugation for 10 
min at 700x g and washed three times in phosphate-buffered saline (PBS), The final 
pellet was resuspended in an equal volume of PBS containing 1% gelatin. Thin blood 
smears were prepared, air dried, and fixed in acetone-methanol (1:1) for 20 min at -20°C. 
Pooled Serum samples (obtained from BALB/c mice of all groups at; n = 5 each group) 
were diluted with PBS in two-fold steps, starting at 1: 80 and tifrated by IIP on fixed P. 
yoelii (MDR) blood stage slides as described elsewhere (Freeman and Holder, 1983) 
before incubating them for 30 min at 37°C. Slides were washed three times in PBS and 
then incubated as above with a fluorescein isothiocyanate-conjugated (FITC) rabbit anti-
mice IgG (Sigma Chemical Company, St. Louis, Mo.) diluted 1:160 in PBS. Stained cells 
were then washed, and were visualized by fluorescence microscopy. The end point was 
determined as highest serum dilution showing clear fluorescence. 
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3.11. Statistical Analysis 
The data were analyzed by one-way analysis of variance (ANOVA) following 
Dunnet's t test method. The survival data was analyzed by Mann Whitney Test. P < 0.05 
was considered statistically significant. 
4. Results 
4.1. Effect of escheriosomes based antigen vehicle on survival and parasitemia 
against lethal Plasmodium yoelii nigeriensis (MDR) blood stage infection: 
As evident from figure 9 & 10, the group of animals immunized with 
escheriosome entrapped sAg showed highest level of protection. On day 6 post infection 
this group showed mean parasitaemia 0.286 + 0.018% (98% parasite suppression with 
respect to PBS injected control animals) [P <0.0001] while animals immunized either 
with EPC/chol liposomes encapsulated sAg or with IFA showed same level of mean 
parasitaemia (~ 2.4 %). All the control group mice that were injected with PBS or sham 
liposomes died by day 8 post-challenge whereas, barring some early deaths in all the 
vaccinated groups, no further mortality was observed on day 10 post-challenge in rest of 
the immunized groups (figure 10). All immunized groups showed protection against P. 
yoelii infection, yet the percentage of animals survived was highest in escheriosome-sAg 
group (70 %) while EPC/chol liposome-sAg and IFA-sAg could completely clear the 
parasite load in only 30 % and 20 % of the animals respectively (figure 10). Interestingly, 
animals immunized with escheriosome-sAg, showed early recovery as they were found to 
be virtually fi-ee from parasite burden (100 % suppression) on day 16 post challenge 
(figure 9). 
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Figure 9: Effect of immunization with different formulations of sAg on 
parasitaemia. Groups of all experimental as well as control BALB/c mice (n = 10 
each group) were challenged with 10^  parasitized RBCs of lethal Plasmodium 
yoelii nigeriensis (MDR) intraperitoneally (i.p.) at day 7 post final booster. The 
percent parasitemia was determined by examining Geimsa stained thin blood 
smears of individual mice taken at 2-days interval. 
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Figure 10: Effect of immunization with different formulations of sAg on 
survival ofBALB/c mice. Groups of all experimental as well as control BALB/c 
mice (n = 10 each group) were challenged with 10^  parasitized RBCs of lethal 
Plasmodium yoelii nigeriensis (MDR) intraperitoneally (i.p.) at day 7 post final 
booster. The animals were monitored daily for any mortality. Data are 
representative of three different experiments. 
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Figure 11: Percent population of CD8^ T-cells following immunization of 
BALB/c mice. The freshly isolated spleen cells from the BALB/c mice of all 
experimental and control groups (n = 5 each group) were pooled and stained with 
FITC conjugated anti-CD8a monoclonal Abs (Sigma) as described in M&M 
before analyzing them by FACS (BD Biosciences). The cells with log 
fluorescence intensities > 10' were gated as CD8^ T-cells and compared in the 
histogram. X-axis parameter: Log fluorescence of FITC-CD8^ T-cells; Y-axis 
parameter: counts of CD8^ T-Cells which are positive for the marker used. The 
isotype control showed a background value of 0.4%. Sham liposome immunized 
animals showed a marginal level of positive cells. 
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Figure 12: Percent population of CD4* T-cells following immunization of 
BALB/c mice. The freshly isolated spleen cells from the BALB/c mice of each 
experimental and control groups (n = 5 each group) were pooled and stained with 
FITC conjugated anti-CD4 monoclonal Abs (Sigma) before analyzing them by 
FACS (BD Biosciences). The cells with log fluorescence intensities > lO' were 
gated as CD4^ T-cells and compared in the histogram. X-axis parameter: Log 
fluorescence of F1TC-CD4^ T-cells; Y-axis parameter: counts of CD4^ T-Cells 
which are positive for the marker used. The isotype control showed a background 
value of 0.4%. Sham liposome immunized animals showed a marginal level of 
positive cells. 
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Figure 13: Spleenocytes proliferation assay. Spleen cells (IxlO^/well) were 
isolated from all the immunized as well as control mice (n = 5 each group) and 
cultured with matching formulations viz. free sAg, escheriosome entrapped sAg 
and sAg encapsulated in EPC/chol liposome encapsulated sAg. After 72h, ^[H]-
thymidine was added, and its incorporation was measured 16h later by liquid 
scintillation spectroscopy. The stimulation index (SI) was calculated as: 
(mean cpm values of stimulated culture / mean cpm values of unstimulated 
culture). Control cultures containing cells obtained from mice either injected with 
PBS or sham escheriosomes gave background levels of <1000 cpm of "[H]-
thymidine incorporation. Data are mean + S.D. for three different experiments. 
P values: Escheriosome-sAg Vs PBS controK 0.001; Vs EPC <0.01 
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4.2. Escheriosome encapsulated sAg elicits malaria specific CD4* and CDS T cell 
immunity in BALB/c mice: 
Immunization with sAg entrapped in the escheriosomes, but not with its other 
forms viz. IFA-sAg or sAg entrapped in EPC/chol liposomes generated high CD8^ as 
well as CD4^ T-cell populations. A considerably higher degree (25.2 %) of CD8^ T-cells 
were found among the spleenocytes obtained from the animals receiving escheriosome 
encapsulated sAg immunization, as compared to other groups of animals immunized with 
either IFA-sAg or sAg incorporated into EPC/chol liposomes [P<0.001] (figure 11). 
Moreover, there was a substantial increase in CD4* T-cell population upon immunization 
with the escheriosome-sAg form of antigen (27.2%) (figure 12). Although, mice 
immunized with EPC/chol liposome entrapped sAg showed an increase in CD4^ T-cells 
(18.1%) as compared to the control animals (2.6%), however, it was substantially less to 
that of receiving escheriosome-sAg immunization. IFA-sAg immunized animals showed 
only marginal increase in both T-cell populations [CD4^ 11.7% and CD8^ 9.5%; (figure 
11 «& 12)]. Group of mice immunized with sham escheriosomes showed marginal 
positive cells similar to PBS-control (CD8^ 0.4% and CD4^ 2.0%). 
Moreover, escheriosome-sAg combination was found to induce strong 
spleenocytes proliferation as well (S.I. value > 6). Among other formulations of the sAg 
only EPC/chol liposome-sAg induced significant proliferation (S.I. = 2.9), while 
immunization with IFA-sAg failed to elicit significant level of proliferation (S.I. < 2) 
(figure 13). Control sets containing cells obtained from either groups immunized with 
PBS alone or fusogenic lipids only (sham escheriosomes without sAg), gave background 
levels of < 1000 cpm of ^H-thymidine incorporation. 
4.3. Escheriosomes uptake by peritoneal macrophages enhances expression of B7.1 
(CD80) as well as B7.2 (CD86): 
Peritoneal macrophages obtained from thioglycoUate injected BALB/c mice and 
incubated with various formulations of sAg were characterized for expression of 
SO 
Figure 14: Effect of escheriosome mediated sAg delivery upon expression of 
costimulatory molecules (CD80 and CD86). Thioglycollate elicited peritoneal 
macrophages (1 x 10 cells/well) of BALB/c mice were incubated with various 
formulations of sAg for 48 h as described in M&M section. After incubation, cells 
were scrapped and stained with FITC conjugated anti-CD80 or anti-CD86 
monoclonal antibodies (Sigma) to determine CD80 as well as CD86 expression 
levels by FACS analysis (BD Biosciences). The mean fluorescence value (Mf) is 
indicated in the upper right comer of each histogram. Data are representative of 
results from three independent experiments. Control cells (stimulated with PBS 
only) showed background of 0.8 and 1.2 Mf values for CD 80 and CD 86 
respectively. 
81 
Free-sAg EPC/chol Lip-sAg EL Lip-sAg 
10^ ^o•' 
CD 80-FITC 
n 
a s e 
U Free-sAg EPC/chol Lip-sAg EL Lip-sAg 
CD 86-FITC 
Figure 15: Effect of immunization on the secretion of Thl (IFN-y) and Th2 
(IL-4) cytokines. Cultures were performed, as described in M&M for that of 
spleenocytes proliferation assay from mice of all experimental and control groups 
and amounts of cytokines released were assayed by sandwich ELISA as described 
in M&M. The levels of cytokines were calculated by standard curves that were 
plotted using recombinant cytokines (Pharmingen). Data are mean + S.D. for 
three different experiments. 
P values, for IFN-y; EL lip-sAg Vs PBS controKO.OOl, Vs EPC lip-sAg = 0.002. 
For IL-4; EL lip-sAg Vs PBS control = 0.002, Vs EPC lip-sAg = 0.07 
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Figure 16: Effect of immunization upon IgG isotypes. IgG isotype responses in 
various groups immunized with escheriosome entrapped sAg, EPC/chol 
liposomes or in emulsified form with IFA were observed. For that sera obtained 
from the normal and experimental animals (n = 5 each group) were analyzed for 
the presence of malaria-specific IgG isotype by ELISA method as described. The 
levels of IgG isotypes were expressed as absorbance (A495) of the colored 
complex developed in the immunosorbent assay. Data are mean + S.D. for three 
different experiments. 
P values: for IgGl; EL lip-sAg Vs PBS controKO.OOl, Vs EPC lip-sAg = 0.01. 
For IgG2a; EL lip-sAg Vs PBS control<0.01, Vs EPC lip-sAg< 0.01 
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costimulatory molecules (both CD80 and CD86) using specific MAbs by flow cytometry 
(figure 14). After 48 h of incubation, the levels of these markers were increased. 
Escheriosome encapsulated sAg pulsed macrophages showed a clear maturation, with 
increased expression of CD80 and CD86 (Mean fluorescence 41.3 and 34.9 respectively). 
Although EPC/chol liposome-sAg induced increased levels of maturation markers on 
these APCs after 48 h of incubation (CD80 and CD86; Mf value 26.8 and 18.6 
respectively), this level was much lower than observed with escheriosome-sAg 
formulation which again supports an enhanced uptake of escheriosome-sAg through 
membrane-membrane fusion. Much less pronounced effects were observed for free sAg 
(CD80 and CD86; Mf value 9.8 and 14.8 respectively) whereas unstimulated control or 
sham liposome stimulated macrophages showed only marginal mean fluorescence values 
(CD80 and CD86; Mf value < 4.0 & 6.0 respectively). 
4.4. Immunization with escheriosome-entrapped sAg enhances the production of 
protective cytokines: 
We analyzed the spleen cell culture supematants of the BALB/c mice from 
various experimental and control groups for IFN- y and IL-4 production at day 7 post 
final booster (day 35 post primary immunization). Immunization with escheriosome-sAg 
resulted in higher levels of lL-4 (230 + 5.2 pg/mL) and IFN- y (162 + 4.2 pg/mL) as 
compared to mice immunized with EPC/chol liposomes-sAg (IL-4; 180 + 8.0 pg/ml and 
IFN- y; 28+1.7 pg/mL) or IFA-sAg (lL-4; 90 ± 7.1 pg/mL and IFN-y; 16.8 ± 2.5 pg/mL) 
(figure 15). Spleen cells obtained fi'om control group animals or immunized with sham 
escheriosomes produced insignificant marginal levels of cytokines. 
4.5. Escheriosome-sAg immunization enhances IgGl and IgG2a isotype responses: 
The isotype profile of P. yoelii antigen specific antibodies present in the sera of 
all experimental mice was assessed by ELISA method. As shown in figure 16, beside 
IgGl, the other predominant isotype generated by escheriosome encapsulated sAg was 
IgG2a. In contrast, both EPC/chol liposome-sAg and IFA-sAg induced mainly IgGl 
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Figure 17: Immunoblot analysis of antibodies associated with immunization 
induced immunity to P. yoelii. The reactivities of pooled sera obtained from mice 
(n = 5 each group) previously immunized with escheriosome entrapped sAg 
(Lane 2), EPC liposome entrapped sAg (Lane 3) or sAg emulsified with 
incomplete Freund's adjuvant (Lane 4) were assayed on immunoblots of P. yoelii 
blood stage antigen (10 fig/lane) separated by SDS-PAGE on 4 - 17% gradient 
gel. Antigen specific antibodies were detected enzymatically with sheep 
antibodies specific for total mouse IgG. Lane 1 represents prestained marker. 
Serum from either PBS-immunized or sham escheriosome immunized mice did 
not recognize any antigen (Lane 5). 
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Figure 18: Antibody titration by indirect immunofluorescence. IIF assay was 
performed with pooled serum samples from the groups of all experimental and 
control mice (n = 5 each group) as described in M & M. Immunofluorescence of 
pooled sera from IFA-sAg (B), EPC/chol liposome encapsulated sAg (C) and 
escheriosome encapsulated sAg (D), as observed at their end points listed in the 
table. Serum obtained from either PBS-immunized control (A) or sham 
escheriosome immunized mice failed to develop any fluorescence even at the 
dilution 1:80. 
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Figure 19: SDS-PAGE profile of various antigens entrapped in escheriosomes. 
For neglecting the possibility of any protein containment, sham (empty 
escheriosomes) as well as antigen encapsulating escheriosomes were run on SDS-
PAGE gel (12%) and silver stained. Lane 2, shows soluble blood stage antigens 
of P. yoelii (sAg) encapsulated in escheriosomes; Lane 3, sAg alone; Lane 4, 
shows OVA encapsulated in escheriosomes; Lane 5, OVA alone; Lane 6, sham 
escheriosomes while Lane 1 represents prestained marker. 
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antibodies. Moreover, after probing the blots with sera obtained from various immunized 
groups, a heterogeneous set of antigens was observed where sera from escheriosome-sAg 
immunized animals recognized some extra antigens. Serum obtained from sham 
escheriosome immunized or PBS-immunized control mice did not recognize any antigen 
(figure 17). In another set of experiments, we found that IIF titers correlated with the 
highest level of antibody produced as a result of escheriosome-sAg combination (end 
point 1: 20,480), while on the other hand in EPC/chol liposome-sAg and IFA-sAg 
immunized animals the fluorescence finished at the end points 1: 5120 and 1: 2560 
respectively (figure 18). 
5. Discussion 
Earlier studies show that P. yoelii whole blood stage antigens can induce a 
protective immune response in mice in an adjuvant dependent manner (Bums et al., 1997; 
Hunter et ah, 1995). Hence, adjuvants and vaccine carriers are believed to influence 
many parameters of immune system and results from the present study are consistent 
with these findings. We found that vaccination with sAg entrapped in liposomes made up 
of E. coli membrane lipids (escheriosomes) resulted in significant protection against a 
progressive infection of lethal P. yoelii. Immunization with sAg encapsulated in lipid 
vesicles prepared from E. coli lipids showed 98% suppression in the mean parasitemia 
with respect to control animals (22.3% ± 12.8 %) at day 6 post infection [P <0.0001]. 
Moreover, the percentage of animals completely cured was highest in escheriosome-sAg 
immunized group (70 %), compared to other antigen carriers used in the study (figure 10). 
In addition, escheriosome-sAg immunized animals showed early recovery as on day 16 
post challenge mice from this group were free of parasitic burden (figure 9). 
In compliance with the earlier studies, results from the present study suggest that 
antigen may activate different components of immune system to evoke characteristic 
effector responses depending on its delivery mode (Patterson et ah, 1999). For instance, 
sAg entrapped in escheriosomes generates high antigen specific CD8"^  T-cells, compared 
to sAg entrapped in EPC/chol liposomes or mice unmunized with IFA-sAg (figure 11). 
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It is well known that CD8* CTL response plays no role in developing protective 
immunity against blood stage challenges of P. yoelii as the adoptive transfer of CD8"^  T-
cells from immune mice failed to protect animals, while CD8"^  T-cell knockout mice (P2-
M°^ °) resolved their infections with a similar time course like normal mice (Kumar and 
Miller, 1990; Vander Heyde et al., 1993). However, a correlation of CD8^ T-cells in IFN-
y up-regulation suggests that enhanced CD8"^  T-cell response may contribute in the favor 
of Thl response polarization. (Erard and Gros, 1994). 
Because of their tendency to fuse with target cells (APCs), escheriosomes in 
principle deliver the entrapped protein into the cytosol of the APCs for presentation via 
the MHC class I processing pathway. Being particulate in nature they can be readily 
phagocytosed by the cells as well, and it may lead to the processing of delivered antigen 
through the MHC class II route; Hence, besides generating CD8"^  T-cells, the 
escheriosome-sAg combination induced higher CD4"*^  T lymphocyte proliferation as well 
(figure 12 & 13). The other formulations of sAg i.e. EPC/chol liposome or IFA-sAg also 
aided the CD4^ T lymphocyte proliferation but the magnitude was below par to that of 
the former. As optimum activation of Th-cells require not only TCR occupancy by 
presented MHC-antigen complex, but also a set of other costimulatory signals provided 
by APCs (Janway and Bottomly, 1994). Expression of both CD80 and CD86 play major 
role in providing costimulation ,to T-cells, leading to their proliferation, cytokine 
production, and development of effector functions. Higher expression of CD80 and CD86 
as a result of escheriosome-sAg vaccination again supports the enhancement in the 
antigen presentation to APCs eventually supporting the expansion of Th-cells (figure 14) 
Earlier reports indicated that beside strong humoral immunity the control of 
malaria blood stage parasite depends on CD4'*" T-cells that secret IFN- y (Langhome et al., 
2002; Patterson et al., 1999; Mohan and Stevenson, 1998; Batchelder et al., 1997). This 
was again proved in Th-1 or Th-2 cytokine deficient knock-out mice infected with 
malaria where lack of Th-1 cytokines (IL-2 and IFN-y deficient mice) results in 
exacerbated P. yoelii infections and lack of Th-2 cytokines (IL-4 or IL-10) does not affect 
the course of P. yoelii parasitemia in IL-4/IL-10 knock-out mice (Vander Heyde et al.. 
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1993; Vinetz et al, 1990). Hence, we determined the levels of both Thl (IFN- y) and Th-
2 (IL-4) cytokine levels in response to immunization with various sAg formulations. 
After immunization, escheriosome-sAg immunized animals showed a marked increase in 
both Th-l/Th-2 cytokines (IL-4 and IFN- y) while EPC/chol liposome-sAg immunization 
induced upregulation of IL-4 only and amount of IFN- y secreted in this group was 
significantly less (figure 15) [P < 0.001]. Our studies, in conformation with the report of 
Krishnan et al, (2000b) demonstrated that in spite of the fact that Thl/Th2 responses 
may be dichotomous, however depending upon both extrinsic and intrinsic factors, 
antigens may themselves skew immunity towards one or the other form (Agrewala et al., 
1996). Nevertheless the immunogenic property of an antigen can be manipulated using 
adjuvants or suitable delivery systems that enable it to induce both Thl and Th2 responses 
(Conlan et al, 2001; Harding et al, 1991; Patterson et al, 1999; Tuhina et al, 2004). 
Immunization with escheriosome encapsulated sAg resulted in strong humoral 
immune response as well. Beside IgGl, the other predominant isotype generated by 
escheriosome encapsulated sAg was IgG2a (figure 16). In contrast, both EPC/chol 
liposome-sAg and IFA-sAg combination induced IgGl type of the antibodies mainly. 
The up regulation of IgG2a production is attributed to the increased IFN^ level 
(Coffinan et al, 1993). The high protection among animals immunized with 
escheriosome-sAg confirms contribution of IgG2a isotype of the antibodies as in an 
earlier study such antibodies are reported to be efficient in modulating the P. yoelii blood 
stage infection (Wendy et al, 1991). The immunoblots reacted with sera from 
escheriosome-sAg immunized mice clearly demonstrated recognition of some extra 
antigens. It may be inferred from the above data that these antigens may be of protective 
significance (figure 17). Furthermore, data from IIF assay, supports the notion that 
escheriosomes based immunization elicited the highest parasite specific IgG titers among 
all the vaccine formulations tried (figure 18). 
In order to rule out the possibility that some protein/lipopolysaccharide (LPS) 
contamination could be responsible for the observed protective immune responses, we 
tested the isolated E. coli lipid for protein/carbohydrate content by chemical analysis 
90 
(carbohydrate/lipid ratio < 0.0001). The absence of these contaminants was further 
confirmed by SDS-PAGE, which was negative for any protein content upon silver 
staining (figure 19). Moreover, failure of sham escheriosome to elicit any significant 
immune response further confirms that observed protective immune responses in 
immunized animals are because of the escheriosome mediated delivery of sAg. 
Vaccines based on liposomes formulated with lipid A and Alhydrogel have been 
shown to be potent and safe in humans (Fries et ah, 1992; Richards et al., 1998). 
However, adjuvants like lipid A or its analogs, because of their nonspecific adjuvanticity, 
can not be recommended in patients with autoimmune disorders. In contrast 
escheriosome based vaccine elicits antigen specific immune responses mainly because of 
their unique delivery mode, and hence, can be indiscriminately used for patients with 
varying immunological backgrounds. 
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Seemmanif^ 
Development of protective immunity against many pathogens requires fine 
orchestration of both humoral- as well as cell mediated-immunity. While, circulating 
antibodies play crucial role in the elimination of extracellular infections, majority of 
intracellular infections (e.g. malaria, leishmaniasis, candidiasis etc.) require generation of 
CD8"^  cytotoxic T-cells (CTL) in conjunction to strong CD4"^  T-helper cells (Th) because 
such pathogens adapt intracellular parasitism as a strategy to avoid recognition by 
antibodies. Besides, some pathogens (e.g. Plasmodium sp. Chlamydia sp, HIV) introduce 
substantial antigenic variations, which further complicate the process of vaccine 
designing. Ironically, a typical protocol followed in immunization with soluble antigens 
leads to the induction of humoral immune response mainly. In contrast activation of the 
cell-mediated immune response, upon administration of soluble antigens has remained an 
uphill task. This requires strategies to expose antigens to the proteasome machinery, a 
multifunctional protease complex in the cytosol of the APCs, as degradation of protein 
antigens by the cytosolic proteolytic system forms the cardinal step involved in the 
induction of cytotoxic T lymphocytes (CTLs). Therefore to generate a CDS"*" T-
lymphocyte response, this is a prerequisite to delivery antigens into the cytosol of the 
APCs, which is further followed by its processing and presentation along with class I 
major histocompatibility complex (MHC I) molecules. The present study has been 
planned to fulfill the requirement of eliciting desired immune responses against various 
intracellular infections and has been presented in two parts. 
In the first part of the study, we describe a novel method of liposome-based 
vehicle to deliver macromolecules into the cytosol of the target cells. To develop safe and 
effective methods for antigen delivery, we exploited the flisogenic potential of the lipids 
derived fi-om a lower organism, i.e. Escherichia coli (K-12). These lipids were shown to 
induce strong membrane-membrane fusion as evident fi*om resonance energy transfer as 
well as content mixing assays. The degree of fusion with model membrane systems using 
E. coli lipid liposomes (escheriosomes) varied from 40-60%, in contrast to 1-8% 
observed with EPC/chol (egg derived phosphatidylcholine/cholesterol) lipid vesicles, 
depending upon the assay system used. The fusion of escheriosomes with macrophages 
(J774 A.l) was assessed by observing transfer of fluorescent membrane marker (NBD-PE) 
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to J774 A.l cells. Transfer of the membrane fluorescent marker (NBD-PE) by 
escheriosomes to the membranes of J774 A.l cells suggested that these vesicles interact 
by membrane-membrane fusion mode. This was further demonstrated by observed 
inhibition of cellular protein synthesis among J774 A.l cells using escheriosome 
encapsulated 'ricin A'. Thus, it may be concluded that the escheriosomes can 
spontaneously fuse with the membrane of macrophages to deliver a significant portion of 
their contents into the cytoplasmic compartment of the cells. 
In the second part, we evaluated the escheriosomes as an antigen delivery system 
in the immunization studies against blood stage infection of lethal Plasmodium yoelii 
(MDR) in B ALB/c mice. Today, malaria is considered one of the most devastating and 
deadly disease that claim about 1.4 to 2.7 million deaths annually. Furthermore, the 
recent development of resistance of Plasmodium sp. to the chemotherapeutic agents and 
of its vector to DDT, alarm us to opt for alternative weapons for its control. This has led 
to choose prophylactic measures as complementary tools for controlling this dreadful 
disease, which in turn requires understanding of the basic immunological complexities 
involved in the resolution of the disease. However, in spite of the numerous efforts made 
for developing malaria vaccine, no effective malaria vaccine is available today. 
It has been shown that elimination of liver stage Plasmodium infection require 
involvement of CD8"^  CTL response, while immunity against blood stages of malaria is 
dependent on IFN-y secreting €04"^ Th-cells and IgG2a isotype of antibodies. In the 
study, soluble blood stage antigens of P. yoelii (sAg) were encapsulated in escheriosomes 
or EPC/choI liposomes and BALB/c mice were immunized at various days for 
performing protection as well as immunological studies. Other experimental groups 
received sAg with incomplete Freund's adjuvant (IFA), while control groups were 
injected with empty escheriosomes (sham) or PBS only. Results from the study revealed 
that immunization with escheriosome entrapped sAg induced strong protective immune 
responses that successfully suppressed drug resistant P. yoelii infection, whereas other 
formulations of sAg such as EPC/chol liposome entrapped sAg, or sAg with incomplete 
Freund's adjuvant (IFA) failed to impart significant levels of protection. Among all the 
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sAg formulations used in the study, escheriosome based vaccine elicited strongest 
humoral as well as cell mediated immune responses in immunized BALB/c mice. 
The escheriosome-sAg mediated protection was found to be associated with 
enhanced antigen specific CD4"^  and CD8"^  T cell populations. Furthermore, activation of 
Th-cells requires not only TCR occupancy by presented MHC-antigen complex, but also 
a set of other costimulatory signals provided by APCs. hi this concern, costimulatory 
molecules (CD80 and CD86) provide maturation signals to T-lymphocytes, leading to 
their proliferation, cytokine production, and development of effector functions. Higher 
expression of CD80 and CD86 on the macrophages incubated with escheriosome-sAg 
again supports the data representing the expansion of Th cells. Analysis of cytokine 
profiles in immunized animals revealed that the escheriosome mediated delivery of sAg 
was associated with the induction of a mixed Thl/Th2 (IFN-y and IL-4) cytokine 
response. Moreover, vaccination with escheriosome entrapped sAg elicited high IgGl 
and IgG2a isotype responses that played important role in imparting protection against 
blood stage infection of Plasmodium yoelii (MDR) in BALB/c mice. The antibody 
titration by indirect immunofluorescence (IIF) also revealed the presence of high titer 
parasite-specific antibodies in the sera of mice that were immunized with escheriosome 
encapsulated sAg. These high titer antibodies recognized a heterogeneous set of antigens 
on P. yoelii antigens blotted on to nitrocellulose membranes. 
The data of the present study seems to open new vistas for the use of 
escheriosome based vaccines not only against malaria but against various other 
intracellular pathogens as well. 
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